



Dyspareunia in HIV positive and negative middle-aged women

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-004974
Article Type:	Research
Date Submitted by the Author:	04-Feb-2014
Complete List of Authors:	<p>Valadares, Ana; School of Medical Sciences, University of Campinas (UNICAMP), Campinas, Department of Obstetrics and Gynecology; Pinto-Neto, Aarão; School of Medical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil, Department of Obstetrics and Gynecology Gomes, Débora; School of Medical Sciences, University of Campinas (UNICAMP), Campinas, Department of Obstetrics and Gynecology Campinas, Brazil D'Avanzo, Walquíria Moura, Alexandre; Infectious Disease Reference Center, CTR/DIP Orestes Diniz, Municipal Health Division, Federal University of Minas Gerais, Costa-Paiva, Lúcia; School of Medical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil, Department of Obstetrics and Gynecology Sousa, Maria Helena; School of Medical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil, Department of Obstetrics and Gynecology</p>
Primary Subject Heading:	HIV/AIDS
Secondary Subject Heading:	HIV/AIDS, Obstetrics and gynaecology, Sexual health, Infectious diseases
Keywords:	Sexual and gender disorders < PSYCHIATRY, HIV & AIDS < INFECTIOUS DISEASES, SEXUAL MEDICINE, Sexual dysfunction < UROLOGY, PAIN MANAGEMENT

SCHOLARONE™
Manuscripts

Dyspareunia in HIV positive and negative middle-aged women

Ana L. R. Valadares¹, MD, PhD; Aarão M. Pinto-Neto¹, MD, PhD; Debora de C. Gomes¹, MD; Walquíria C. D'Avanzo³, Alexandre S. Moura, MD, PhD², Lúcia Costa-Paiva¹, MD, PhD, Maria Helena de Sousa¹, PhD.

¹ Department of Obstetrics and Gynecology, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.

² Infectious Disease Reference Center, CTR/DIP Orestes Diniz, Municipal Health Division, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.

³ Graduated student of medicine of School of Medical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil

Corresponding author:

Ana Lúcia Ribeiro Valadares

Rua Alexander Fleming, 101, Cidade Universitária Zeferino Vaz, Barão Geraldo 13083-881 Campinas, SP, Brazil

Telephone: 55 19 35219306

Fax: 55 31 35219354

E-mail: anarvaladares@gmail.com

Running title: Dyspareunia in HIV-positive women

Short summary- word count: 29

Abstract- word count: 250

Text- word count: 2646

Key messages

- 41.4% of the HIV-positive middle aged women reported dyspareunia.
- Dyspareunia was mainly associated with vaginal dryness and urinary incontinence.
- HIV was not associated with dyspareunia. We hypothesize that it was because women had few HIV-related symptoms.

Short Summary

Cross-sectional study with 178 HIV-negative and 128 HIV-positive women of 40 to 60 years of age. Dyspareunia was common and was associated principally with vaginal dryness and urinary incontinence.

Abstract

Objectives: To evaluate whether dyspareunia is associated with HIV status in menopausal women and also to assess which factors are associated with dyspareunia in a group of HIV-positive menopausal women. Methods: A cross-sectional study was conducted with 178 HIV-negative and 128 HIV-positive women of 40 to 60 years of age. The Short Personal Experiences Questionnaire (SPEQ) was used to collect data. Sociodemographic, clinical, behavioral and reproductive factors were evaluated, as well as factors related to the HIV infection. Dyspareunia was defined as pain during intercourse. A bivariate analysis and Poisson multiple regression analysis were performed. Results: Overall, 41.4% of the HIV-positive women reported dyspareunia compared to 34.8% of the HIV-negative women ($p = 0.242$). In the HIV-positive women, bivariate analysis revealed an association between dyspareunia and having a steady partner ($p = 0.047$); the woman's partner having undergone HIV

1
2
3 testing ($p = 0.020$); vaginal dryness ($p < 0.001$); muscle/joint pain ($p = 0.021$);
4
5 physical/emotional violence ($p = 0.049$); urinary incontinence ($p = 0.004$); and the
6
7 use of lamivudine/zidovudine ($p = 0.048$). Poisson multiple regression analysis
8
9 found an association between dyspareunia and vaginal dryness (PR=1.96,
10
11 95%CI: 1.10-3.50, $p = 0.023$) and urinary incontinence (PR=1.86, 95%CI: 1.06-
12
13 3.27, $p = 0.031$). Conclusion: Dyspareunia was common in this group of HIV-
14
15 positive women and was associated principally with vaginal dryness and urinary
16
17 incontinence. The importance of treating dyspareunia within the context of
18
19 sexual health in this group of women should be emphasized and appropriate
20
21 management of this issue may reduce the likelihood of lesions on the vaginal
22
23 wall, which may act as a portal of entry for other infections.
24
25
26

27 **Keywords:** HIV; AIDS; dyspareunia; menopause; urogenital atrophy.
28
29
30
31

32 **Strengths and limitations of this study**

33 Strengths:

- 34 • There are few studies on dyspareunia in HIV positive women and almost
35 none in middle-aged ones.
- 36 • We have highlighted the importance of vulvovaginal atrophy and its
37 association with dyspareunia in middle-aged HIV positive women.
- 38 • We have showed that HIV infection was not significantly associated with
39 dyspareunia, probably because HIV positive women had few HIV related
40 symptoms.
- 41 • The results of this study may help physicians to pay attention on
42 vulvovaginal atrophy and its consequences in this group of HIV positive
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

women.

Limitations:

- It's a cross-sectional design study
- There were some differences in the clinical characteristics of the HIV-positive and HIV-negative women.

Introduction

Dyspareunia or pain during sexual intercourse is one of the most common problems reported by menopausal women. The variation in the frequency of dyspareunia probably reflects many issues including sociocultural aspects, the period of observation during which the condition was evaluated (ever, the past year) and the duration or design of the study under discussion (questionnaire wording, participants).¹

For women of all ages, the pain caused by dyspareunia often results in distress, impaired sexual functioning and poor sexual enjoyment, difficulty in relationships and a poorer quality of life. In postmenopausal women, dyspareunia may also intensify personal issues related to aging, body image and health.²

As with most of the sexual difficulties faced by women at midlife and beyond, dyspareunia is typically considered a consequence of declining ovarian hormone levels and is usually attributed to vaginal atrophy;³ however, other factors may also be involved.⁴ In fact, psychosexual and biological factors (including muscular, endocrine, immune, neurological, vascular and iatrogenic factors) that predispose to, precipitate and perpetuate the condition may interact

1
2
3 to different degrees in the individual woman, contributing to a continuum of
4
5 symptoms of increasing severity, with the potential to impair sexual intercourse.

6
7 ⁵ Age, ⁶ depression, nervousness and sexual dysfunction in the partner ^{4,5} are
8
9 some other factors associated with dyspareunia.

10
11 Menopausal women who are HIV-positive may present a unique set of issues
12
13 that could affect their sexuality. These issues may include the meaning of their
14
15 illness, their quality of life, HIV transmissibility, and the dilemma of whether or
16
17 not to disclose the condition to their partner. Florence et al. reported sexual
18
19 dysfunction to be common in HIV-positive women, principally as a result of their
20
21 HIV status and of psychological factors that included depression, irritability and
22
23 anxiety. ⁷ On the other hand, women with better mental health, a more positive
24
25 attitude towards living with HIV, a better quality of life, fewer HIV-related
26
27 symptoms and who had never used injectable drugs were found to have better
28
29 sexual functioning. ⁸ A possible role of antiretroviral drugs in causing sexual
30
31 dysfunction has been a matter of debate. Whereas some studies have
32
33 suggested that antiretroviral therapy indeed plays a role in sexual function,
34
35 others have failed to find any such association. ⁹

36
37
38 The majority of studies on dyspareunia have failed to deal with factors
39
40 associated with the HIV infection, a topic yet to be fully investigated in HIV-
41
42 positive women during the aging process. Therefore, the objectives of the
43
44 present study were to evaluate whether dyspareunia is associated with HIV
45
46 status in middle-aged women and to assess the factors associated with
47
48 dyspareunia in HIV-positive middle-aged women.

49 50 51 52 53 54 55 56 **Methods**

Study design

A cross-sectional study was conducted in which 537 women of 40 to 60 years of age, 273 of whom were HIV-positive and 264 HIV-negative, were screened for inclusion. These women were receiving care at the infectious diseases and HIV outpatient clinics at the Teaching Hospital of the University of Campinas (UNICAMP), at the genital infections and the menopausal outpatient clinics of CAISM/UNICAMP, and at the infectious diseases outpatient clinic of the Eduardo de Menezes Hospital in Belo Horizonte were invited to participate in the study. Of these, 178 HIV- negative women and 128 HIV- positive women had had vaginal intercourse in the previous month and were willing to answer a questionnaire on dyspareunia. These women were then admitted to the study.

The evaluation instrument was based on the Short Personal Experiences Questionnaire (SPEQ).^{10,11} Sociodemographic, clinical, behavioral and reproductive characteristics were assessed as well as issues relating to the HIV infection and partner-related factors.

Blood samples were collected at the moment of admission in the present study, and the rapid test was carried out and compared with the gold standard (ELISA and Western blot).

Sample size

Sample size was calculated by estimating the prevalence of sexual dysfunction in HIV-negative menopausal women at 35.9%¹² and the prevalence of sexual dysfunction in HIV-positive women at 60.0%.¹³ To enable comparisons to be drawn between the HIV-positive and HIV-negative groups, the number of women required was calculated at 74 per group for an alpha error of 0.05 and a

1
2
3 beta error of 0.20; however, to enable analysis to be made of the HIV-positive
4
5 group alone, the required number was 188 women (with a difference of 7
6
7 percentage points). Since the actual sample size achieved was 128, the
8
9 absolute difference was 8.5%.

10 11 12 13 14 ***Dependent variable***

15
16 Dyspareunia was defined as pain during sexual intercourse in accordance with
17
18 a pain intensity score of 2 or more within a scale of 1 to 6.
19

20 21 22 23 ***Independent variables***

24
25 The independent variables were dichotomized as follows: HIV status (positive /
26
27 negative); skin color (white / other); marital status (has a stable partner/ no
28
29 stable partner); schooling (≤ 7 years / ≥ 8 years); employment (yes: / no);
30
31 monthly family income (\leq USD750 / $>$ USD750); receives pension (yes / no);
32
33 smokes (yes / never or past smoker); alcohol use (currently drinks or used to
34
35 drink / never drank); hot flushes (yes / no); depression (yes / no); vaginal
36
37 dryness (yes / no); urinary incontinence (yes / no); weight gain (yes / no);
38
39 muscle and joint pain (yes / no); self-perception of health (excellent or good /
40
41 poor or very poor); suffers or has already suffered some form of physical or
42
43 emotional violence (yes / no); has been forced to have intercourse (yes / no);
44
45 uses statins (yes / no); chronic disease: hypothyroidism (yes / no); LH (<25.7 / \geq
46
47 25.7); age at first sexual intercourse (≤ 19 years / ≥ 20 years); other type of
48
49 sexual intercourse in the preceding month: active oral sex (yes / no); passive
50
51 oral sex (yes / no); woman lives with sexual partner (yes / no); menopausal
52
53 status: (pre- or perimenopausal/ menopausal); number of sexual partners in the
54
55
56
57
58
59
60

1
2
3 previous year (none / ≥ 1); partner underwent HIV testing (yes / no); quality of
4 life following diagnosis (changed / unchanged); CD4 cell count (<350 / ≥ 350);
5 CD4 cell count nadir (<199 ; ≥ 200); use of antiretroviral drug 3TC (Lamivudine,
6
7 Epivir) (yes/ no); use of antiretroviral drug Tenofovir (yes / no); use of
8
9 antiretroviral drug lamivudine/zidovudine (yes / no); use of antiretroviral drug
10
11 Efavirenz (yes / no); antiretroviral drug used in the past: lamivudine/zidovudine
12
13 (yes / no); antiretroviral drug used in the past: Efavirenz (yes/ no).
14
15
16
17
18
19

20 ***Statistical analysis***

21
22 A bivariate analysis was performed in which dyspareunia was considered the
23 dependent variable and analyzed as a function of the independent variables.
24
25 Pearson's chi square test and the Yates correction were used to compare the
26
27 groups.¹⁴ The Poisson multiple regression analysis¹⁵ was adjusted in the
28
29 various models for each one of the independent variables to evaluate the
30
31 factors associated with the presence of dyspareunia.
32
33
34
35
36
37

38 ***Ethics***

39
40 The study was approved by the internal review board of CAISM/UNICAMP and
41
42 was conducted in compliance with the current version of the Declaration of
43
44 Helsinki and with Resolution 196/96 of the Brazilian National Committee for
45
46 Ethics in Research (CONEP) and its subsequent revisions. This study forms
47
48 part of a larger study evaluating menopausal symptoms, bone mass, sexual
49
50 function and metabolic markers. Process: CEP: 407/2010, CAAE
51
52 0313.0.146.000-10.
53
54
55
56
57
58
59
60

1
2
3 Women who agreed to participate in the study after receiving instructions from
4 the researchers and who signed a free informed consent form were included.
5
6
7
8
9
10

11 12 **Results**

13
14
15
16
17 The HIV-positive women were younger and less likely to have a steady partner,
18 to be employed or to have a formal education compared to the HIV-negative
19 women. More than half the HIV-positive women were pre- or perimenopausal.
20
21 The characteristics of the women interviewed are shown in Table 1.
22
23

24
25 Overall, 41.4% (n=53) of the HIV-positive women and 34.8% (n=62) of the
26 HIV-negative women reported dyspareunia. There was no association
27 between HIV status and dyspareunia (p=0.242) (data not shown as table).
28
29 Furthermore, in the multiple regression analysis of the entire sample of HIV-
30 positive and HIV-negative women taken together (n=306), dyspareunia was
31 not associated with HIV status, but was associated with vaginal dryness
32 (PR=2.06, 95%CI: 1.37-3.10, p=0.001) and urinary incontinence (PR=1.68,
33 95%CI: 1.14-2.46, p=0.008). Predictive variables considered: HIV status
34 (positive / negative); skin color (white / other); marital status (has a stable
35 partner/ no stable partner); schooling (≤ 7 years / ≥ 8 years); employment
36 (yes: / no); monthly family income (\leq R\$1.500 / $>$ R\$1500); receives pension
37 (yes / no); smokes (yes / never or past smoker); alcohol use (currently
38 drinks or used to drink / never drank); hot flushes (yes / no); depression (yes
39 / no); vaginal dryness (yes / no); urinary incontinence (yes / no); weight gain
40 (yes / no); muscle and joint pain (yes / no); self-perception of health
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 (excellent or good / poor or very poor); suffers or has already suffered some
4 form of physical or emotional violence (yes / no); has been forced to have
5 intercourse (yes / no); uses statins (yes / no); chronic disease:
6 hypothyroidism (yes / no); LH (<25.7 / ≥ 25.7); age at first sexual intercourse
7 (≤ 19 years / ≥ 20 years); other type of sexual intercourse in the preceding
8 month: active oral sex (yes / no); passive oral sex (yes / no); woman lives
9 with sexual partner (yes / no); menopausal status: (pre- or perimenopausal/
10 menopausal); number of sexual partners in the previous year (none / ≥ 1).

11
12
13
14
15
16
17
18
19
20
21 (Table not presented).

22
23 In the HIV-positive group, 91.4% of the women were currently in use of
24 antiretroviral therapy (ART) and, of these, 87% reported using ART regularly
25 (data not presented as table). Approximately 77% of the HIV-positive women
26 had a CD4 cell count nadir >200. The most common way in which HIV had
27 been acquired was by heterosexual transmission, and the average duration of
28 the HIV infection was 9.5 ± 5.6 years (mean ± SD), with a mean duration of
29 therapy of 8.7 years ±4.5 (mean ± SD). A more detailed description of the HIV-
30 infected women is provided in Table 2.

31
32 Bivariate analysis revealed an association between dyspareunia in the HIV-
33 positive women and having a steady partner (p=0.047); the woman's partner
34 having undergone HIV testing (p=0.020); vaginal dryness (p<0.001);
35 muscle/joint pain (p=0.021); physical/emotional violence (p=0.049); urinary
36 incontinence (p=0.004); and the use of lamivudine/zidovudine (p=0.048),

37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52 Table 3.

53
54
55 According to the Poisson multiple regression analysis, the principal factors
56 associated with dyspareunia in the group of HIV-positive women were: vaginal
57
58
59
60

1
2
3 dryness (PR = 1.96; 95%CI: 1.10- 3.50; p=0.023) and urinary incontinence
4
5 (PR=1.86; 95%CI: 1.06-3.27; p = 0.031) (Table 4).
6
7
8

9 **Discussion**

10
11
12
13
14 The objectives of this study were to evaluate whether HIV status was
15
16 associated with dyspareunia and to assess the factors associated with pain
17
18 during sexual intercourse in HIV-positive women of 40 to 60 years of age.
19
20 Information on dyspareunia in HIV positive women is scarce, especially in
21
22 middle-aged women. To the best of our knowledge, no other studies have been
23
24 conducted on dyspareunia in HIV-positive women of 40 to 60 years of age. It
25
26 has been reported that sexual function in HIV-positive women may be driven
27
28 principally by psychological factors and by HIV status.^{13,16} The present study,
29
30 however, found that in the overall sample of HIV-positive and negative women
31
32 dyspareunia was not affected by HIV status. This finding is in agreement with
33
34 the results of another author, who also reported that few women believed HIV in
35
36 itself to be the cause of any decline in their sexual functioning, since those
37
38 women had few HIV-related symptoms.⁸
39
40
41
42

43 In the present study, more than three-quarters of the HIV-positive patients had a
44
45 CD4 cell count nadir > 200 and CD4 cell counts > 500 in their last evaluation,
46
47 reflecting adequate control of the disease. This may partially explain why no
48
49 association was found between HIV status and dyspareunia. In line with this,
50
51 another study showed that women with CD4 counts ≤199 cells/μL reported
52
53 poorer sexual functioning compared to those whose cell count was ≥ 200.¹⁷
54
55
56
57
58
59
60

1
2
3 Other studies have shown that CD4 cell count nadir may also have long-term
4
5 consequences in terms of prognosis and mortality.¹⁸
6

7
8 Nevertheless, the CD4 cell count nadir and the last CD4 evaluation were not
9
10 associated with dyspareunia in the present study, probably because of the small
11
12 number of women with these low values.

13
14 The most important factors associated with dyspareunia in the logistic
15
16 regression analysis, in HIV positive and negative groups, were vaginal dryness
17
18 and urinary incontinence, both of which are urogenital disorders associated with
19
20 estrogen deficiency. The association between vaginal dryness and pain during
21
22 sexual intercourse has been well documented in the literature.^{19,20} With
23
24 respect to the association between urinary incontinence and dyspareunia, the
25
26 findings of the present study are in agreement with the results published by
27
28 Salonia et al., who compared 216 women with urinary incontinence to healthy
29
30 women without any urinary symptoms and found 44% of dyspareunia in women
31
32 with urinary incontinence.²¹ The type of urinary incontinence was not
33
34 evaluated in the present study. Nevertheless, there is good evidence that the
35
36 effects of urinary incontinence on sexual functioning are similar irrespective of
37
38 whether the condition has been classified as stress, urge or mixed incontinence.
39
40 Urinary incontinence leads to feelings of embarrassment and inadequacy as
41
42 well as low self-esteem. It may also lead to dyspareunia.²²
43
44

45
46 In the bivariate analysis, the fact that the woman's partner had not been tested
47
48 for HIV was associated with less dyspareunia. It is reasonable to speculate that
49
50 not knowing her partner's HIV status may in some way "minimize" a woman's
51
52 concerns regarding transmission and reduce the probability of tension and
53
54 dyspareunia.²³ Another factor related to the sexual partner that was
55
56
57
58
59
60

1
2
3 associated with an increase in dyspareunia in the bivariate analysis was the
4 woman having a steady partner. One explanation for this finding may lie in the
5 psychological problems generated by the infection itself, which may arise more
6 frequently in stable relationships.^{23,24}
7
8
9
10

11
12 Results of the bivariate analysis revealed an association between
13 physical/emotional violence and dyspareunia. Violence is known to be
14 associated with poorer psychological adjustment and adverse sexual health
15 outcomes in women.^{25,26} In addition, having muscle pain was associated with
16 dyspareunia in the bivariate analysis. This finding is in line with another study
17 showing that musculoskeletal pain often interferes with sex and may be
18 associated with dyspareunia.²⁷ A borderline association was found between the
19 use of lamivudine/zidovudine and dyspareunia; however, no explanation for
20 this association was found in the literature.
21
22
23
24
25
26
27
28
29
30
31

32
33 Some limitations to the present study must be taken into account. First, its
34 cross-sectional design does not permit any conclusions to be drawn with
35 respect to causality. Furthermore, there were some differences in the clinical
36 characteristics of the HIV-positive and HIV-negative women. These differences
37 could be attributed to the fact that the HIV-negative women were selected at
38 specialist outpatient clinics providing care to menopausal women.
39
40
41
42
43
44
45

46 Nevertheless, multivariate analysis, conducted in a sufficiently large sample of
47 women after controlling for confounding factors, confirmed that HIV infection
48 was not significantly associated with dyspareunia. Good control of the HIV
49 infection and the regular use of antiretroviral therapy by the majority of the
50 women may have brought this group of women closer to the HIV-negative group
51 in terms of their characteristics.
52
53
54
55
56
57
58
59
60

Conclusions

In this study population, HIV infection was not associated with the presence of dyspareunia. The principal factors associated with dyspareunia in HIV-positive women were vaginal dryness and urinary incontinence. These data indicate a need for multidisciplinary care for HIV-positive menopausal women, paying particular attention to ensuring the women's compliance with antiretroviral therapy and offering improved care when these two clinical situations are present to ensure that these women come as close as possible in this respect to HIV-negative women. Greater attention to dyspareunia as a potential component of women's general HIV and sexual care is warranted. A proactive approach to conversations about vulvovaginal atrophy would improve management of dyspareunia and vaginal dryness. In addition to improving the quality of these women's sexual life, we hypothesize that appropriate management of this issue may reduce the likelihood of lesions on the vaginal wall, which may act as a portal of entry for other infections.

Financial Support: The São Paulo Foundation for the Support of Research (*Fundação de Amparo à Pesquisa do Estado de São Paulo - FAPESP*), Grant # 2010/06037-5.

Competing Interest: None declared.

Licence statement

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence on a worldwide basis to the BMJ Group and co-owners or contracting owning societies (where

1
2
3 published by the BMJ Group on their behalf), and its Licensees to permit this
4
5 article (if accepted) to be published in Sexually Transmitted Infections and any
6
7 other BMJ Group products and to exploit all subsidiary rights, as set out in our
8
9 licence.
10

11 Ana L R Valadares

12 **Extra data**

13
14
15
16 The instrument used to collect data is available by emailing

17
18 anarvaladares@gmail.com
19

20 **List of contributors and their role in the paper**

21
22 Conception or design of the work

23 Ana L. R. Valadares; Aarão M. Pinto-Neto; Lúcia Costa-Paiva

24
25 Acquisition of data for the work

26 Ana L. R. Valadares; Debora de C. Gomes, MD; Walquíria C. D'Avanzo,
27 Alexandre S. Moura
28
29

30
31 Analysis of data for the work

32 Maria Helena de Sousa, Ana L. R. Valadares; Aarão M. Pinto-Neto; Lúcia
33 Costa-Paiva
34

35 Interpretation of data for the work

36 Ana L. R. Valadares; Aarão M. Pinto-Neto; Lúcia Costa-Paiva, Maria Helena de
37 Sousa
38

39
40 Drafting the work or revising it critically for intellectual content

41 Ana L. R. Valadares; Aarão M. Pinto-Neto; Lúcia Costa-Paiva; Debora de C.
42 Gomes, MD; Walquíria C. D'Avanzo, Alexandre S. Moura, Maria Helena de
43 Sousa
44

45 Final approval of the version to be published

46 Ana L. R. Valadares; Aarão M. Pinto-Neto; Lúcia Costa-Paiva; Debora de C.
47 Gomes, MD; Walquíria C. D'Avanzo, Alexandre S. Moura, Maria Helena de
48 Sousa
49
50
51
52
53
54
55
56
57
58
59
60

References

- 1 Kao A, Binik YM, Kapuscinski A, Khalife S. Dyspareunia in
2 postmenopausal women: a critical review. *Pain Res Manag* 2008;13:243-
3 254.
- 4 Sung SC, Jeng CJ, Lin YC. Sexual health care for women with
5 dyspareunia. *Taiwan J Obstet Gynecol* 2011;50:268-274.
- 6 Lachowsky M, Nappi RE. The effects of oestrogen on urogenital health.
7 *Maturitas* 2009;63:149-151.
- 8 Valadares AL, Pinto-Neto AM, Conde DM, Sousa MH, Osis MJ, Costa-
9 Paiva L. A population-based study of dyspareunia in a cohort of middle-
10 aged Brazilian women. *Menopause* 2008;15:1184-1190.
- 11 Graziottin A. Etiology and diagnosis of coital pain. *J Endocrinol Invest*
12 2003;26(3 Suppl):115-121.
- 13 Avis NE, Zhao X, Johannes CB, Ory M, Brockwell S, Greendale GA.
14 Correlates of sexual function among multi-ethnic middle-aged women:
15 results from the Study of Women's Health Across the Nation (SWAN).
16 *Menopause* 2005;12:385-398.
- 17 Florence E, Schrooten W, Dreezen C, et al.; Eurosupport Study Group.
18 Prevalence and factors associated with sexual dysfunction among HIV-
19 positive women in Europe. *AIDS Care* 2004;16:550-557.
- 20 Bova C, Durante A. Sexual functioning among HIV-infected women.
21 *AIDS Patient Care STDS* 2003;17:75-83.
- 22 Collazos J. Sexual dysfunction in the highly active antiretroviral therapy
23 era. *AIDS Rev* 2007;9:237-245.

- 1
2
3 10 Dennerstein L, Anderson-Hunt M, Dudley E. Evaluation of a short scale
4 to assess female sexual functioning. *J Sex Marital Ther* 2002;28:389-
5 397.
6
7
8
9
10 11 Valadares AL, Pinto-Neto AM, de Sousa MH, Osis MJ. [Sociocultural
11 adaptation of the short personal experiences questionnaire (SPEQ) in
12 Brazil]. *Rev Bras Ginecol Obstet* 2010;32:72-76.
13
14
15 12 Valadares AL, Pinto-Neto AM, Osis MJ, Sousa MH, Costa- Paiva L,
16 Conde DM. Prevalence of sexual dysfunction and its associated factors
17 in women aged 40-65 years with 11 years or more of formal education: a
18 population-based household survey. *Clinics* 2008;63:775-782.
19
20
21 13 Lambert S, Keegan A, Petrak J. Sex and relationships for HIV positive
22 women since HAART: a quantitative study. *Sex Transm Infect*
23 2005;81:333-337.
24
25
26 14 Altman DG. *Practical statistics for medical research*. Boca Raton, FL:
27 Chapman & Hall/CRC, 1999.
28
29
30 15 Barros AJ, Hirakata VN. Alternatives for logistic regression in cross-
31 sectional studies: an empirical comparison of models that directly
32 estimate the prevalence ratio. *BMC Med Res Methodol* 2003;3:21.
33
34
35 16 Bell C, Richardson D, Wall M, Goldmeier D. HIV-associated female
36 sexual dysfunction: clinical experience and literature review. *Int J STD*
37 *AIDS* 2006;17:706-709.
38
39
40 17 Wilson TE, Jean-Louis G, Schwartz R, et al. HIV infection and women's
41 sexual functioning. *J Acquir Immune Defic Syndr* 2010;54:360-367.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 18 Bray S, Gedeon J, Hadi A, et al. Predictive value of CD4 cell count nadir
4 on long-term mortality in HIV-positive patients in Uganda. HIV AIDS
5 2012;4:135-140.
6
7
8
9
10 19 Laumann EO, Nicolosi A, Glasser DB, et al.; GSSAB Investigators'
11 Group. Sexual problems among women and men aged 40-80y:
12 prevalence and correlates identified in the Global Study of Sexual
13 Attitudes and Behaviors. Int J Impot Res 2005;17:39-57.
14
15
16
17
18 20 Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly
19 associated with female sexual dysfunction among sexually active
20 postmenopausal women. Menopause 2008;15(4 Pt 1):661-666.
21
22
23
24
25 21 Salonia A, Zanni G, Nappi RE, et al. Sexual dysfunction is common in
26 women with lower urinary tract symptoms and urinary incontinence:
27 results of a cross-sectional study. Eur Urol 2004;45:642-648.
28
29
30
31
32 22 Urwitz-Lane R, Ozel B. Sexual function in women with urodynamic stress
33 incontinence, detrusor overactivity, and mixed urinary incontinence. Am J
34 Obstet Gynecol 2006;195(6):1758-61
35
36
37
38
39 23 Reis RK, Gir E. [Living with the difference: the impact of serodiscordance
40 on the affective and sexual life of HIV/AIDS patients]. Rev Esc Enferm
41 USP 2010;44:759-765.
42
43
44
45 24 Klusmann D. Sexual motivation and the duration of partnership. Arch Sex
46 Behav 2002;31:275-287.
47
48
49
50 25 Laanpere M, Ringmets I, Part K, Karro H. Intimate partner violence and
51 sexual health outcomes: a population-based study among 16-44-year-old
52 women in Estonia. Eur J Public Health 2013;23:688-693.
53
54
55
56
57
58
59
60

- 1
2
3 26 Leclerc B, Bergeron S, Binik YM, Khalifé S. History of sexual and
4
5 physical abuse in women with dyspareunia: association with pain,
6
7 psychosocial adjustment, and sexual functioning. *J Sex Med* 2010;7(2 Pt
8
9 2):971-980.
10
11
12 27 Rosenbaum TY. Musculoskeletal pain and sexual function in women. *J*
13
14 *Sex Med* 2010;7(2 Pt 1):645-653.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1– Characteristics of women according to HIV status

Characteristic	Group		p Value
	HIV-infected (%) (n=128)	HIV-uninfected (%) (n=178)	
Age (years)			
40 – 44	43.8	24.7	<0,002 #
45 – 49	28.9	29.2	
50 – 54	15.6	23.1	
≥ 55	11.7	23,0	
Race/ethnicity			
White	35.2	47.2	0,047 &
Non-White	64.8	52.8	
Number of deliveries			
Up to 1	25.0	25.4	>0.999 &
≥2	75.0	74.6	
Marital status			
With partner	58.6	87.1	<0,001 &
Without partner	41.4	12.9	
Schooling (years)			
≤7	62.5	40,4	<0,002 #
8-11	23.4	37,1	
≥12	14.1	22,5	
Employment status			

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Yes	59.4	71.9	0.030 &
No	40.6	28.1	
Menopausal status			
Premenopausal	39.8	24.7	<0,002 #
Perimenopausal	28.1	21.4	
Postmenopausal	32.1	53.9	
Smoking habit			
Yes/ Former	28,1	15.2	0,009 &
No	71,9	84.8	
Physical activity			
Up to 2 times/week	77.3	74.2	0,614 &
≥3 times/week	22.7	25.8	

* Sample of women with partner and information on occurrence or not of dyspareunia in the last month

Pearson's Chi-square; & Yates's Chi-square

Table 2 – Characteristics associated to HIV status associated with dyspareunia in women with sexual partner in the month before the interview (n=128)

Characteristics	N	%
Nadir CD4 levels (a)		
0 – 100	18	14.5
101 – 200	10	8.1
201 – 500	62	50.0
> 500	34	27.4
Last CD4 levels (a)		
0 – 100	5	4.0
101 – 200	1	0.8
201 – 500	43	34.7
> 500	75	60.5
Total	124	100.0
HIV risk factor for acquisition		
heterosexual <i>acquisition</i>	97	75.8

Illicit drug use	3	2.3
blood transfusion	2	1.6
Não sabe/ Não respondeu	26	20.3
Total	128	100.0

Use of TARV

Yes	117	91.4
No	11	8.6
Total	128	100.0

HIV duration of infection (n=125) Mean: 9.5 SD: 5.06
(years)

Duration of HIV therapy (n=93) Mean: 8.7 SD: 4.47
(years)

(a) Missing information

Table 3 – Factors associated with dyspareunia (score ≥ 2) in middle-aged HIV positive women: bivariate analysis

Variable	Dyspareunia%		p *
	N	Score ≥ 2	
Marital status			0.047
Married/live together	75	49.3	50.7
Don't live together	53	30.2	69.8
Did partner have HIV test?			0.020
Yes	88	50.0	50.0
No	27	22.2	77.8
Vaginal dryness			<0.001
Yes	53	58.5	41.5
No	71	26.8	73.2
Muscular / articular pain			0.021
Yes	83	49.4	50.6
No	45	26.7	73.3
Physical/ Emotional violence			0,049

1				
2				
3	Yes	128	55.5	44.5
4				
5	No	174	32.8	67.2
6				
7				
8	Urinary Incontinence			
9				
10				0,004
11				
12	Yes	41	61.0	39.0
13				
14	No	87	32.2	67.8
15				
16				
17				
18				
19	Use of biovir			
20				0.048
21				
22				
23	Yes	57	29.8	70.2
24				
25	No	63	49.2	50.8
26				
27				
28				
29				
30				
31				
32				

Predictive variables considered: skin color (white / other); marital status (has a stable partner/ no stable partner); schooling (≤ 7 years / ≥ 8 years); employment (yes: / no); monthly family income (\leq R\$1.500 / $>$ R\$1500); receives pension (yes / no); smokes (yes / never or past smoker); alcohol use (currently drinks or used to drink / never drank); hot flushes (yes / no); depression (yes / no); vaginal dryness (yes / no); urinary incontinence (yes / no); weight gain (yes / no); muscle and joint pain (yes / no); self-perception of health (excellent or good / poor or very poor); suffers or has already suffered some form of physical or emotional violence (yes / no); has been forced to have intercourse (yes / no); uses statins (yes / no); chronic disease: hypothyroidism (yes / no); LH (<25.7 / ≥ 25.7); age at first sexual intercourse (≤ 19 years / ≥ 20 years); other type of sexual intercourse in the preceding month: active oral sex (yes / no); passive oral sex (yes / no); woman lives with sexual partner (yes / no); menopausal status: (pre- or perimenopausal/ menopausal); number of sexual partners in the previous year (none / ≥ 1); partner underwent HIV testing

1
2
3 (yes / no); quality of life following diagnosis (changed / unchanged); CD4 cell count (<350 /
4 ≥ 350); CD4 cell count nadir (<199; ≥ 200); use of antiretroviral drug 3TC (Lamivudine,
5 Epivir) (yes/ no); use of antiretroviral drug Tenofovir (yes / no); use of antiretroviral drug
6 Lamivudine/zidovudine (yes / no); use of antiretroviral drug Efavirenz (yes / no);
7
8 antiretroviral drug used in the past: Lamivudine/zidovudine (yes / no); antiretroviral drug
9 used in the past: Efavirenz (yes/ no).
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Tabela 4 – Variables associated with dyspareunia in HIV positive women with sexual partner in the month before the interview. Poisson multiple regression [n=124]

Variable	PR	95%CI	p-value
Vaginal dryness	1.96	1.10 – 3.50	0.023
Urinary incontinence	1.86	1.06 – 3.27	0.031

PR: prevalence ratio; CI 95%: 95% confidence interval; p: p-value

Predictive variables considered: skin color (white / other); marital status (has a stable partner/ no stable partner); schooling (≤ 7 years / ≥ 8 years); employment (yes: / no); monthly family income (\leq R\$1.500 / $>$ R\$1500); receives pension (yes / no); smokes (yes / never or past smoker); alcohol use (currently drinks or used to drink / never drank); hot flushes (yes / no); depression (yes / no); vaginal dryness (yes / no); urinary incontinence (yes / no); weight gain (yes / no); muscle and joint pain (yes / no); self-perception of health (excellent or good / poor or very poor); suffers or has already suffered some form of physical or emotional violence (yes / no); has been forced to have intercourse (yes / no); uses statins (yes / no); chronic disease: hypothyroidism (yes / no); LH (<25.7 / ≥ 25.7); age at first sexual intercourse (≤ 19 years / ≥ 20 years); other type of sexual intercourse in the preceding month: active oral sex (yes / no); passive oral sex (yes / no); woman lives with sexual partner (yes / no); menopausal status: (pre- or perimenopausal/ menopausal); number of sexual partners in the previous year (none / ≥ 1); partner underwent HIV testing (yes / no); quality of life following diagnosis (changed / unchanged); CD4 cell count (<350 / ≥ 350); CD4 cell count nadir (<199 ; ≥ 200); use of antiretroviral drug 3TC (Lamivudine, Epivir) (yes/ no); use of antiretroviral drug Tenofovir (yes / no); use of antiretroviral drug

1
2
3 Lamivudine/zidovudine (yes / no); use of antiretroviral drug Efavirenz (yes / no);
4 antiretroviral drug used in the past: Lamivudine/zidovudine (yes / no); antiretroviral drug
5 used in the past: Efavirenz (yes/ no).
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

checklist **Dyspareunia in HIV positive and negative middle-aged women**

	Item No	Recommendation
okTitle and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Ok background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Ok Objectives	3	State specific objectives, including any prespecified hypotheses
Methods		
Ok Study design	4	Present key elements of study design early in the paper
Ok Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Ok Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Ok Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Ok Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Ok Bias	9	Describe any efforts to address potential sources of bias
Ok Study size	10	Explain how the study size was arrived at
Ok Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Ok Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses

Continued on next page

Results

Ok Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Ok Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Ok Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Ok Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Ok Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

Discussion

Ok Key results	18	Summarise key results with reference to study objectives
Ok Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Ok Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Ok Generalisability	21	Discuss the generalisability (external validity) of the study results

Other information

Ok Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
------------	----	---

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Dyspareunia in HIV positive and negative middle-aged women: a cross sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-004974.R1
Article Type:	Research
Date Submitted by the Author:	19-Jun-2014
Complete List of Authors:	<p>Valadares, Ana; School of Medical Sciences, University of Campinas (UNICAMP), Campinas, Department of Obstetrics and Gynecology; Pinto-Neto, Aarão; School of Medical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil, Department of Obstetrics and Gynecology</p> <p>Gomes, Débora; School of Medical Sciences, University of Campinas (UNICAMP), Campinas, Department of Obstetrics and Gynecology Campinas, Brazil</p> <p>D'Avanzo, Walquíria; University of Campinas, Graduated student of medicine of School of Medical Sciences, Department of Obstetrics and Gynecology</p> <p>Moura, Alexandre; Infectious Disease Reference Center, CTR/DIP Orestes Diniz, Municipal Health Division, Federal University of Minas Gerais, Costa-Paiva, Lúcia; School of Medical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil, Department of Obstetrics and Gynecology</p> <p>Sousa, Maria Helena; School of Medical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil, Department of Obstetrics and Gynecology</p>
Primary Subject Heading:	HIV/AIDS
Secondary Subject Heading:	HIV/AIDS, Obstetrics and gynaecology, Sexual health, Infectious diseases
Keywords:	Sexual and gender disorders < PSYCHIATRY, HIV & AIDS < INFECTIOUS DISEASES, SEXUAL MEDICINE, Sexual dysfunction < UROLOGY, PAIN MANAGEMENT

SCHOLARONE™
Manuscripts

1
2
3 **Dyspareunia in HIV positive and negative middle-aged women: a cross –**
4 **sectional study**
5

6
7 Ana L. R. Valadares¹, MD, PhD; Aarão M. Pinto-Neto¹, MD, PhD; Debora de C.
8
9 Gomes¹, MD; Walquíria C. D'Avanzo³, Alexandre S. Moura, MD, PhD², Lúcia
10
11 Costa-Paiva¹, MD, PhD, Maria Helena de Sousa¹, PhD.
12
13

14
15
16 ¹ Department of Obstetrics and Gynecology, School of Medical Sciences,
17
18 University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.
19

20
21 ² Infectious Disease Reference Center, CTR/DIP Orestes Diniz, Department of
22
23 Municipal Health Division, Federal University of Minas Gerais, Belo Horizonte,
24
25 MG, Brazil.
26

27
28 ³ Graduated student of medicine of School of Medical Sciences, Department of
29
30 Obstetrics and Gynecology, University of Campinas (UNICAMP), Campinas,
31
32 São Paulo, Brazil
33

34 **Corresponding author:**

35
36 Ana Lúcia Ribeiro Valadares

37
38 Rua Alexander Fleming, 101, Cidade Universitária Zeferino Vaz, Barão Geraldo
39
40 13083-881 Campinas, SP, Brazil

41
42 Telephone: 55 19 35219306

43
44 Fax: 55 31 35219354

45
46 E-mail: anarvaladares@gmail.com
47

48
49 **Running title:** Dyspareunia in HIV-positive women

50
51 **Short summary- word count:** 29

52
53 **Abstract- word count:** 250

54
55 **Text- word count:** 2786
56
57
58
59
60

Abstract

Objectives: To evaluate whether dyspareunia is associated with HIV status in menopausal women and also to assess which factors are associated with dyspareunia in a group of HIV-positive menopausal women. Methods: A cross-sectional study was conducted with 178 HIV-negative and 128 HIV-positive women of 40 to 60 years of age. The Short Personal Experiences Questionnaire (SPEQ) was used to collect data. Sociodemographic, clinical, behavioral and reproductive factors were evaluated, as well as factors related to the HIV infection. Dyspareunia was defined as pain during intercourse. A bivariate analysis and Poisson multiple regression analysis were performed. Results: Overall, 41.4% of the HIV-positive women reported dyspareunia compared to 34.8% of the HIV-negative women ($p = 0.242$). In the HIV-positive women, bivariate analysis revealed an association between dyspareunia and having a steady partner ($p = 0.047$); the woman's partner having undergone HIV testing ($p = 0.020$); vaginal dryness ($p < 0.001$); muscle/joint pain ($p = 0.021$); physical/emotional violence ($p = 0.049$); urinary incontinence ($p = 0.004$); and the use of lamivudine/zidovudine ($p = 0.048$). Poisson multiple regression analysis found an association between dyspareunia and vaginal dryness (PR=1.96, 95%CI: 1.10-3.50, $p = 0.023$) and urinary incontinence (PR=1.86, 95%CI: 1.06-3.27, $p = 0.031$). Conclusion: Dyspareunia was common in this group of HIV-positive women and was associated principally with vaginal dryness and urinary incontinence. The importance of treating dyspareunia within the context of sexual health in this group of women should be emphasized and appropriate management of this issue may reduce the likelihood of lesions on the vaginal wall, which may act as a portal of entry for other infections.

1
2
3 **Keywords:** HIV; AIDS; dyspareunia; menopause; urogenital atrophy.
4
5
6

7 **Strengths and limitations of this study**
8

9 Strengths:
10

- 11
- 12 • We have not found studies on dyspareunia in HIV positive women.
 - 13
 - 14 • We have highlighted the importance of vulvovaginal atrophy and its
15 association with dyspareunia in middle-aged HIV positive women.
 - 16
 - 17 • We have showed that HIV infection was not significantly associated with
18 dyspareunia, probably because HIV positive women had few HIV related
19 symptoms.
 - 20
 - 21 • The results of this study may help physicians to pay attention on
22 vulvovaginal atrophy and its consequences in this group of HIV positive
23 women.
24
25
26
27
28
29
30
31

32 Limitations:
33

- 34 • It's a cross-sectional design study
- 35
- 36 • There were some differences in the clinical characteristics of the HIV-
37 positive and HIV-negative women.
38
39
40
41
42

43 **Key messages**
44

- 45 • 41.4% of the HIV-positive middle aged women reported dyspareunia.
- 46
- 47 • Dyspareunia was mainly associated with vaginal dryness and urinary
48 incontinence.
- 49
- 50 • HIV was not associated with dyspareunia. We hypothesize that it was
51 because HIV positive women had good immunovirological status.
52
53
54
55
56
57
58
59
60

Short Summary

Cross-sectional study with 178 HIV-negative and 128 HIV-positive women of 40 to 60 years of age. Dyspareunia was common and was associated principally with vaginal dryness and urinary incontinence.

Introduction

Dyspareunia is defined as persistent or recurrent genital pain that occurs just before, during or after intercourse. It is one of the most common problems reported by menopausal women. The variation in the frequency of dyspareunia probably reflects many issues including sociocultural aspects, the period of observation during which the condition was evaluated (ever, the past year) and the duration or design of the study under discussion (questionnaire wording, participants).¹

For women of all ages, the pain caused by dyspareunia often results in distress, impaired sexual functioning and poor sexual enjoyment, difficulty in relationships and a poorer quality of life. In postmenopausal women, dyspareunia may also intensify personal issues related to aging, body image and health.²

As with most of the sexual difficulties faced by women at midlife and beyond, dyspareunia is typically considered a consequence of declining ovarian hormone levels and is usually attributed to vaginal atrophy;³ however, other factors may also be involved.⁴ In fact, psychosexual and biological factors (including muscular, endocrine, immune, neurological, vascular and iatrogenic factors) that predispose to, precipitate and perpetuate the condition may interact to different degrees in the individual woman, contributing to a continuum of

1
2
3 symptoms of increasing severity, with the potential to impair sexual
4 intercourse⁵. Age,⁶ depression, anxiety and sexual dysfunction in the partner
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

4,5 are some other factors associated with dyspareunia. It seems that cognitive-emotional variables (catastrophization, depression, anxiety) are significant predictors of dyspareunia and relationship adjustment variables were inversely associated with pain severity⁷ Findings also suggest that dyspareunia impacts not only the psychosexual adjustment of affected women but also that of their partners.⁸

Menopausal women who are HIV-positive may present a unique set of issues that could affect their sexuality. These issues may include the meaning of their illness, their quality of life, HIV transmissibility, and the dilemma of whether or not to disclose the condition to their partner. Florence et al. reported sexual dysfunction to be common in HIV-positive women, principally as a result of their HIV status and of psychological factors that included depression, irritability and anxiety.⁹ On the other hand, women with better mental health after HIV diagnosis, a more positive attitude towards living with HIV, a better quality of life, fewer HIV-related symptoms and who had never used injectable drugs were found to have better sexual functioning.¹⁰ A possible role of antiretroviral drugs in causing sexual dysfunction has been a matter of debate. Whereas some studies have suggested that antiretroviral therapy indeed plays a role in sexual function, others have failed to find any such association.¹¹

The majority of studies on dyspareunia have failed to deal with factors associated with the HIV infection, a topic yet to be fully investigated in HIV-positive women during the aging process. Therefore, the objectives of the present study were to evaluate whether dyspareunia is associated with HIV

1
2
3 status in middle-aged women and to assess the factors associated with
4
5 dyspareunia in HIV-positive middle-aged women.
6
7

8 9 **Methods**

10 11 ***Study design***

12
13
14 A cross-sectional study was conducted in which 537 women of 40 to 60 years of
15
16 age, 273 of whom were HIV-positive and 264 HIV-negative were screened for
17
18 inclusion. Patients were recruited at the infectious diseases and HIV outpatient
19
20 clinics (HIV positive women) and at the menopausal ambulatory care (HIV
21
22 negative women), both at the Teaching Hospital of the University of Campinas
23
24 (UNICAMP). Patients were also invited to participate at the infectious diseases
25
26 outpatient public clinic (HIV positive women) in Belo Horizonte. Of these, 178
27
28 HIV- negative women and 128 HIV- positive women had had vaginal
29
30 intercourse in the previous month and were willing to answer a questionnaire on
31
32 dyspareunia. These women were then admitted to the study.
33
34
35
36
37
38

39 For inclusion in the HIV-positive group, laboratory confirmation of the women's
40
41 seropositive status by one of the recommended tests (ELISA or Western Blot)
42
43 was required (all of them had it), while the women recruited to the HIV-negative
44
45 group had to have tested negative. The blood samples tests of HIV negative
46
47 and positive women were collected at the moment of admission in the present
48
49 study (FSH, LH and TSH for all, ELISA or Western Blot HIV tests for HIV
50
51 negative women and Viral load and CD4 cells for HIV positive women .
52
53

54 Exclusion criteria consisted of nursing mothers, bilaterally oophorectomized
55
56 women and those unable to answer the questionnaire. The evaluation
57
58
59
60

1
2
3 instrument was the Short Personal Experiences Questionnaire (SPEQ).^{12,13}
4
5 Sociodemographic, clinical, behavioral and reproductive characteristics were
6
7 assessed as well as issues relating to the HIV infection and partner-related
8
9 factors.
10

11 12 13 14 ***Dependent variable***

15
16 The dependent variable dyspareunia, defined as pain during sexual intercourse,
17
18 was graded from 1 to 6, where 1 referred to the absence of pain and 6 to
19
20 maximum pain. A score of less than 2 was considered to represent the absence
21
22 of dyspareunia and a score of 2 or more to represent the presence of
23
24 dyspareunia.^{12,13,14}
25
26

27 ***Independent variables***

28
29
30
31 The independent variables were dichotomized as follows: HIV status (positive /
32
33 negative); skin color (white / other); marital status (has a stable partner/ no
34
35 stable partner); schooling (≤ 7 years / ≥ 8 years); employment (yes: / no);
36
37 monthly family income (\leq USD750 / $>$ USD750); receives pension (yes / no);
38
39 smokes (yes / never or past smoker); alcohol use (currently drinks or used to
40
41 drink / never drank); hot flushes (yes / no); depression (yes / no); vaginal
42
43 dryness (yes / no); urinary incontinence (yes / no); weight gain (yes / no);
44
45 muscle and joint pain (yes / no); self-perception of health (excellent or good /
46
47 poor or very poor); suffers or has already suffered some form of physical or
48
49 emotional violence (yes / no); has been forced to have intercourse (yes / no);
50
51 uses statins (yes / no); chronic disease: hypothyroidism (yes / no);
52
53
54
55
56
57
58
59
60

1
2
3 FSH (<40/≥40), LH (<25.7 / ≥ 25.7); age at first sexual intercourse (≤ 19 years /
4 ≥ 20 years); other type of sexual intercourse in the preceding month: giving oral
5 sex (yes / no); receiving oral sex (yes / no); woman lives with sexual partner
6 (yes / no); number of sexual partners in the previous year (none / ≥ 1); partner
7 underwent HIV testing (yes / no); quality of life following diagnosis (changed /
8 unchanged); CD4 cell count (<350 / ≥ 350); CD4 cell count nadir (<199; ≥ 200);
9 use of antiretroviral drug 3TC (Lamivudine, Efavirenz) (yes/ no); use of antiretroviral
10 drug Tenofovir (yes / no); use of antiretroviral drug lamivudine/zidovudine (yes /
11 no); use of antiretroviral drug Efavirenz (yes / no); antiretroviral drug used in the
12 past: lamivudine/zidovudine (yes / no); antiretroviral drug used in the past:
13 Efavirenz (yes/ no). Menopausal status was classified as premenopausal,
14 perimenopausal or postmenopausal. Women were considered premenopausal
15 if they continued to have regular menstrual cycles similar to those present
16 during the woman's reproductive life. They were considered to be in the
17 perimenopause if their menstrual cycles were irregular and they had been
18 amenorrheic for less than 12 months. Finally, women were classified as
19 postmenopausal if they had been amenorrheic for 12 months or more.¹⁵ Data
20 on physical activity was obtained through two questions: Do you practice
21 physical exercise or participate in sports every week? How often in a week do
22 you practice physical exercise or participate in sports?. It was classified in up
23 to two times a week or 3 or more times a week. Vaginal lubrication during sexual
24 activity was graded from 1 to 6, where 1 referred to the absence of lubrication
25 and 6 to maximum lubrication. This was dichotomized into 4 or less
26 or more than 4.

Statistical analysis

1
2
3 A bivariate analysis was performed in which dyspareunia was considered the
4 dependent variable (dyspareunia) and analyzed as a function of the
5
6 independent variables. Pearson's chi square test and the Yates correction were
7
8 used to compare the groups.¹⁶ The Poisson multiple regression analysis¹⁷
9
10 was adjusted in the various models for each one of the independent variables to
11
12 evaluate the factors associated with the presence of dyspareunia.
13
14
15

16 17 18 **Ethics**

19
20 The study was approved by the internal review board of CAISM/UNICAMP and
21
22 was conducted in compliance with the current version of the Declaration of
23
24 Helsinki and with Resolution 196/96 of the Brazilian National Committee for
25
26 Ethics in Research (CONEP) and its subsequent revisions. This study forms
27
28 part of a larger study evaluating menopausal symptoms, bone mass, sexual
29
30 function and metabolic markers. Process: CEP: 407/2010, CAAE
31
32 0313.0.146.000-10.
33
34
35

36
37 Women who agreed to participate in the study after receiving instructions from
38
39 the researchers and who signed a free informed consent form were included.
40
41

42 **Results**

43
44 The HIV-positive women were younger and less likely to have a steady partner,
45
46 to be employed or to have a formal education compared to the HIV-negative
47
48 women. More than half the HIV-positive women were pre- or perimenopausal.

49
50 The characteristics of the women interviewed are shown in Table 1.

51
52 Overall, 41.4% (n=53) of the HIV-positive women and 34.8% (n=62) of the
53
54 HIV-negative women reported dyspareunia. There was no association
55
56 between HIV status and dyspareunia (p=0.242). Furthermore, in the
57
58
59
60

1
2
3 multiple regression analysis of the entire sample of HIV-positive and HIV-
4
5 negative women taken together (n=306), dyspareunia was not associated
6
7 with HIV status, but was associated with vaginal dryness (PR=2.06, 95%CI:
8
9 1.37-3.10, p=0.001) and urinary incontinence (PR=1.68, 95%CI: 1.14-2.46,
10
11 p=0.008).

12
13
14 In the HIV-positive group, 91.4% of the women were currently in use of
15
16 antiretroviral therapy (ART) and, of these, 87% reported using ART regularly
17
18 (data not presented as table). Approximately 77% of the HIV-positive women
19
20 had a CD4 cell count nadir >200. The most common way in which HIV had
21
22 been acquired was by heterosexual transmission, and the average duration of
23
24 the HIV infection was 9.5 ± 5.6 years (mean ± SD), with a mean duration of
25
26 therapy of 8.7 years ±4.5 (mean ± SD). A more detailed description of the HIV-
27
28 infected women is provided in Table 2.

29
30 Bivariate analysis revealed an association between dyspareunia in the HIV-
31
32 positive women and having a steady partner (p=0.047); the woman's partner
33
34 having undergone HIV testing (p=0.020); vaginal dryness (p<0.001);
35
36 muscle/joint pain (p=0.021); physical/emotional violence (p=0.049); urinary
37
38 incontinence (p=0.004); and the use of lamivudine/zidovudine (p=0.048),
39
40
41
42
43

44 Table 3.

45
46 According to the Poisson multiple regression analysis, the principal factors
47
48 associated with dyspareunia in the group of HIV-positive women were: vaginal
49
50 dryness (PR = 1.96; 95%CI: 1.10- 3.50; p=0.023) and urinary incontinence
51
52 (PR=1.86; 95%CI: 1.06-3.27; p = 0.031) (Table 4).

53 54 55 56 57 **Discussion**

1
2
3 The objectives of this study were to evaluate whether HIV status was
4
5 associated with dyspareunia and to assess the factors associated with pain
6
7 during sexual intercourse in HIV-positive women of 40 to 60 years of age.
8
9 The calculated number of women required for the sample size was at 74 per
10
11 group¹⁴; however, to enable analysis of the HIV-positive group alone, the
12
13 required number was 188 women¹⁸. Since the actual sample size achieved was
14
15 128, the absolute difference was 8.5%, acceptable since it is less than 10%.
16
17 Information on dyspareunia in HIV positive women is scarce, especially in
18
19 middle-aged women. To the best of our knowledge, no other studies have been
20
21 conducted on dyspareunia in HIV-positive women. It has been reported that
22
23 sexual function in HIV-positive women may be driven principally by
24
25 psychological factors and other problems related to HIV infection.^{18,19} The
26
27 present study, however, found that in the overall sample of HIV-positive and
28
29 negative women dyspareunia was not affected by HIV status. This finding is in
30
31 agreement with the results of another author, who also reported that few women
32
33 believed HIV in itself to be the cause of any decline in their sexual functioning,
34
35 since those women had good immunovirological status¹⁰ One supposes that
36
37 results would be different in a sample of women without a good HIV control. In
38
39 the present study, more than three-quarters of the HIV-positive patients had a
40
41 CD4 cell count nadir > 200 and CD4 cell counts > 500 in their last evaluation,
42
43 thus reflecting adequate control of the disease. This may partially explain why
44
45 no association was found between HIV status and dyspareunia. In line with
46
47 this, another study showed that women with CD4 counts ≤ 199 cells/ μ L reported
48
49 poorer sexual functioning compared to those whose cell count was ≥ 200 .²⁰
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Other studies have shown that CD4 cell count nadir may also have long-term
4 consequences in terms of prognosis and mortality.²¹
5
6

7 Nevertheless, the CD4 cell count nadir and the last CD4 evaluation were not
8 associated with dyspareunia in the present study, probably because of the small
9 number of women with these low values.
10
11

12
13 The most important factors associated with dyspareunia in the logistic
14 regression analysis, in HIV positive and negative groups analyzed together and
15 in the HIV group analysis were vaginal dryness and urinary incontinence, both
16 of which are urogenital disorders associated with estrogen deficiency. The
17 association between vaginal dryness and pain during sexual intercourse has
18 been well documented in the literature, in addition to its consequence on
19 vulvovaginal health.^{22,23,24} With respect to the association between urinary
20 incontinence and dyspareunia, the findings of the present study are in
21 agreement with the results published by Salonia et al., evaluated 216 women
22 with urinary incontinence and found 44% of dyspareunia in these women.²⁵
23
24

25 The type of urinary incontinence was not evaluated in the present study.
26
27 Nevertheless, there is good evidence that the effects of urinary incontinence on
28 sexual functioning are similar irrespective of whether the condition has been
29 classified as stress, urge, mixed incontinence²⁶ or even interstitial cystitis²⁷
30 Urinary incontinence is associated with feelings of embarrassment and
31 inadequacy as well as low self-esteem. It may also be associated to
32 dyspareunia.²⁵
33
34

35 Factors associated with dyspareunia in HIV positive women:
36
37

38 In the bivariate analysis, the fact that the woman's partner had not been tested
39 for HIV was associated with less dyspareunia. It is reasonable to speculate that
40
41
42
43
44
45
46
47
48
49
50

1
2
3 not knowing her partner's HIV status may in some way "minimize" a woman's
4 concerns regarding transmission and reduce the probability of tension and
5 dyspareunia.²⁸ Another factor related to the sexual partner that was
6 associated with an increase in dyspareunia in the bivariate analysis was the
7 woman having a steady partner, although this association was borderline,. One
8 explanation for this finding may lie in the psychological problems generated by
9 the infection itself, which may arise more frequently in stable relationships.^{28,29}
10 As one has not controlled for frequency of intercourse, one thought is
11 dyspareunia due a lower frequency of intercourse rather than quality of the
12 relationship. Results of the bivariate analysis revealed an association between
13 physical/emotional violence and dyspareunia. Violence is known to be
14 associated with poorer psychological adjustment and adverse sexual health
15 outcomes in women.^{30,31} In addition, having muscle pain was associated with
16 dyspareunia in the bivariate analysis. This finding is in line with another study
17 showing that musculoskeletal pain often interferes with sex and may be
18 associated with dyspareunia.³² A borderline association was found between the
19 use of lamivudine/zidovudine and dyspareunia; however, no explanation for this
20 association was found in the literature. One may hypothesize that dyspareunia
21 in these women could be due depression side effects of these drugs.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49 Some limitations to the present study must be taken into account. First, its
50 cross-sectional design does not permit any conclusions to be drawn with
51 respect to causality. It is also important to note that it was a clinical sample. So,
52 the results found in the present study may not be extrapolated to the general
53
54
55
56
57
58
59
60

1
2
3 population. Furthermore, there were some differences in the clinical
4
5 characteristics of the HIV-positive and HIV-negative women. These differences
6
7 could be attributed to the fact that the HIV-negative women were selected at
8
9 specialist outpatient clinics providing care to menopausal women. By selecting
10
11 HIV positive women also in menopausal outpatient care, maybe groups would
12
13 be similar. Nevertheless, multivariate analysis, conducted in a sufficiently large
14
15 sample of women after controlling for confounding factors, confirmed that HIV
16
17 infection was not significantly associated with dyspareunia. Good control of the
18
19 HIV infection and the regular use of antiretroviral therapy by the majority of the
20
21 women may have brought this group of women closer to the HIV-negative group
22
23 in terms of their characteristics.
24
25
26
27
28

29 **Conclusions**

30
31 In this study population, HIV infection was not associated with the presence of
32
33 dyspareunia. The principal factors associated with dyspareunia in HIV-positive
34
35 women were vaginal dryness and urinary incontinence. These data indicate a
36
37 need for multidisciplinary care for HIV-positive menopausal women, paying
38
39 particular attention to ensuring the women's compliance with antiretroviral
40
41 therapy and offering improved care when these two clinical situations are
42
43 present to ensure that these women come as close as possible in this respect
44
45 to HIV-negative women. Greater attention to dyspareunia as a potential
46
47 component of women's general HIV and sexual care is warranted. A proactive
48
49 approach to conversations about vulvovaginal atrophy would improve
50
51 management of dyspareunia and vaginal dryness. In addition to improving the
52
53 quality of these women's sexual life, we hypothesize that appropriate
54
55
56
57
58
59
60

1
2
3 management of this issue may reduce the likelihood of lesions on the vaginal
4
5 wall, which may act as a portal of entry for other infections.
6
7

8
9
10 **Financial Support:** The São Paulo Foundation for the Support of Research
11
12 (*Fundação de Amparo à Pesquisa do Estado de São Paulo - FAPESP*), Grant #
13
14 2010/06037-5.
15

16 **Competing Interest:** None declared.
17

18 **Licence statement**

19
20 The Corresponding Author has the right to grant on behalf of all authors and
21
22 does grant on behalf of all authors, an exclusive licence on a worldwide basis
23
24 to the BMJ Group and co-owners or contracting owning societies (where
25
26 published by the BMJ Group on their behalf), and its Licensees to permit this
27
28 article (if accepted) to be published in Sexually Transmitted Infections and any
29
30 other BMJ Group products and to exploit all subsidiary rights, as set out in our
31
32 licence.
33
34

35
36 Ana L R Valadares
37
38
39

40 **List of contributors and their role in the paper**

41
42 Conception or design of the work

43 Ana L. R. Valadares; Aarão M. Pinto-Neto; Lúcia Costa-Paiva
44
45

46 Acquisition of data for the work

47 Ana L. R. Valadares; Debora de C. Gomes, MD; Walquíria C. D'Avanzo,
48 Alexandre S. Moura
49

50 Analysis of data for the work

51 Maria Helena de Sousa, Ana L. R. Valadares; Aarão M. Pinto-Neto; Lúcia
52 Costa-Paiva
53
54

55 Interpretation of data for the work

56 Ana L. R. Valadares; Aarão M. Pinto-Neto; Lúcia Costa-Paiva, Maria Helena de
57 Sousa
58
59
60

1
2
3
4 Drafting the work or revising it critically for intellectual content

5 Ana L. R. Valadares; Aarão M. Pinto-Neto; Lúcia Costa-Paiva; Debora de C.
6 Gomes, MD; Walquíria C. D'Avanzo, Alexandre S. Moura, Maria Helena de
7 Sousa
8

9 Final approval of the version to be published

10 Ana L. R. Valadares; Aarão M. Pinto-Neto; Lúcia Costa-Paiva; Debora de C.
11 Gomes, MD; Walquíria C. D'Avanzo, Alexandre S. Moura, Maria Helena de
12 Sousa
13

14
15
16 **Competing interests:** None declared
17

18
19 As corresponding author, I confirm that I have collected ICMJE Uniform
20

21 Disclosure Forms for Potential Conflicts of Interest from every author and no
22

23 Conflicts of Interest exist for any of the authors.
24

25
26 **Extra data**
27

28 We have used a questionnaire to collect data for the present study.

29 The instrument used to collect data is available by emailing

30 anarvaladares@gmail.com
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

- 1 Kao A, Binik YM, Kapuscinski A, Khalife S. Dyspareunia in
2 postmenopausal women: a critical review. *Pain Res Manag* 2008;13:243-
3 254.
- 4 Sung SC, Jeng CJ, Lin YC. Sexual health care for women with
5 dyspareunia. *Taiwan J Obstet Gynecol* 2011;50:268-274.
- 6 Lachowsky M, Nappi RE. The effects of oestrogen on urogenital health.
7 *Maturitas* 2009;63:149-151.
- 8 Valadares AL, Pinto-Neto AM, Conde DM, et al. A population-based
9 study of dyspareunia in a cohort of middle-aged Brazilian women.
10 *Menopause* 2008;15:1184-1190.
- 11 Graziottin A. Etiology and diagnosis of coital pain. *J Endocrinol Invest*
12 2003;26(3 Suppl):115-121.
- 13 Avis NE, Zhao X, Johannes CB, et al. Correlates of sexual function
14 among multi-ethnic middle-aged women: results from the Study of
15 Women's Health Across the Nation (SWAN). *Menopause* 2005;12:385-
16 398.
- 17 Kao A, Binik YM, Amsel R, et al. Biopsychosocial predictors of
18 postmenopausal dyspareunia: the role of steroid hormones, vulvovaginal
19 atrophy, cognitive-emotional factors, and dyadic adjustment. *J Sex Med.*
20 2012 Aug;9(8):2066-76.
- 21 Pazmany E, Bergeron S, Verhaeghe J, et al. Sexual Communication,
22 Dyadic Adjustment, and Psychosexual Well-Being in Premenopausal
23 Women with Self-Reported Dyspareunia and Their Partners: A
24

- 1
2
3 Controlled Study. *J Sex Med*. 2014 Apr 1. doi: 10.1111/jsm.12518. [Epub
4 ahead of print]
5
6
7
- 8 9 Florence E, Schrooten W, Dreezen C, et al.; Eurosupport Study Group.
10 Prevalence and factors associated with sexual dysfunction among HIV-
11 positive women in Europe. *AIDS Care* 2004;16:550-557.
12
13
- 14 10 Bova C, Durante A. Sexual functioning among HIV-infected women.
15 *AIDS Patient Care STDS* 2003;17:75-83.
16
17
- 18 11 Collazos J. Sexual dysfunction in the highly active antiretroviral therapy
19 era. *AIDS Rev* 2007;9:237-245.
20
21
- 22 12 Dennerstein L, Anderson-Hunt M, Dudley E. Evaluation of a short scale
23 to assess female sexual functioning. *J Sex Marital Ther* 2002;28:389-
24 397.
25
26
- 27 13 Valadares AL, Pinto-Neto AM, et al.. [Sociocultural adaptation of the
28 short personal experiences questionnaire (SPEQ) in Brazil]. *Rev Bras*
29 *Ginecol Obstet* 2010;32:72-76.
30
31
- 32 14 Valadares AL, Pinto-Neto AM, Conde DM, et al. A population-based study of
33 dyspareunia in a cohort of middle-aged Brazilian women. *Menopause*.
34 2008;15(6):1184-90
35
36
- 37 15 Soules MR, Sherman S, Parrott E, et al. Executive summary: Stages of
38 Reproductive Aging Workshop (STRAW) Park City, Utah, July, 2001.
39 *Menopause* 2001;8:402-407.
40
41
- 42 16 Lambert S, Keegan A, Petrak J. Sex and relationships for HIV positive
43 women since HAART: a quantitative study. *Sex Transm Infect*
44 2005;81:333-337.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 17 Altman DG. Practical statistics for medical research. Boca Raton, FL:
4 Chapman & Hall/CRC, 1999.
5
6
7 18 Barros AJ, Hiraakata VN. Alternatives for logistic regression in cross-
8 sectional studies: an empirical comparison of models that directly
9 estimate the prevalence ratio. BMC Med Res Methodol 2003;3:21.
10
11
12
13 19 Bell C, Richardson D, Wall M, et al. HIV-associated female sexual
14 dysfunction: clinical experience and literature review. Int J STD AIDS
15 2006;17:706-709.
16
17
18
19 20 Wilson TE, Jean-Louis G, Schwartz R, et al. HIV infection and women's
20 sexual functioning. J Acquir Immune Defic Syndr 2010;54:360-367.
21
22
23
24 21 Bray S, Gedeon J, Hadi A, et al. Predictive value of CD4 cell count nadir
25 on long-term mortality in HIV-positive patients in Uganda. HIV AIDS
26 2012;4:135-140.
27
28
29
30 22 Laumann EO, Nicolosi A, Glasser DB, et al.; GSSAB Investigators'
31 Group. Sexual problems among women and men aged 40-80y:
32 prevalence and correlates identified in the Global Study of Sexual
33 Attitudes and Behaviors. Int J Impot Res 2005;17:39-57.
34
35
36
37 23 Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly
38 associated with female sexual dysfunction among sexually active
39 postmenopausal women. Menopause 2008;15(4 Pt 1):661-666.
40
41
42
43 24 Parish SJ, Nappi RE, Krychman ML, et al. Impact of vulvovaginal health on
44 postmenopausal women: a review of surveys on symptoms of vulvovaginal
45 atrophy. Int J Womens Health. 2013 Jul 29;5:437-47.
46
47
48
49 25 Salonia A, Zanni G, Nappi RE, et al. Sexual dysfunction is common in
50 women with lower urinary tract symptoms and urinary incontinence:
51 results of a cross-sectional study. Eur Urol 2004;45:642-648.
52
53
54
55
56
57
58
59
60

- 1
2
3 26 Urwitz-Lane R, Ozel B. Sexual function in women with urodynamic stress
4
5 incontinence, detrusor overactivity, and mixed urinary incontinence. *Am J*
6
7 *Obstet Gynecol* 2006;195(6):1758–61
8
9
10 27 Wehbe SA, Kellogg S, Whitmore K. Urogenital complaints and female
11
12 sexual dysfunction. Part 2. *J Sex Med.* 2010 Jul;7(7):2304-17
13
14 28 Reis RK, Gir E. [Living with the difference: the impact of serodiscordance
15
16 on the affective and sexual life of HIV/AIDS patients]. *Rev Esc Enferm*
17
18 *USP* 2010;44:759-765.
19
20 29 Klusmann D. Sexual motivation and the duration of partnership. *Arch Sex*
21
22 *Behav* 2002;31:275-287.
23
24 30 Laanpere M, Ringmets I, Part K, et al. Intimate partner violence and
25
26 sexual health outcomes: a population-based study among 16-44-year-old
27
28 women in Estonia. *Eur J Public Health* 2013;23:688-693.
29
30 31 Leclerc B, Bergeron S, Binik YM, et al. History of sexual and physical
31
32 abuse in women with dyspareunia: association with pain, psychosocial
33
34 adjustment, and sexual functioning. *J Sex Med* 2010;7(2 Pt 2):971-980.
35
36 32 Rosenbaum TY. Musculoskeletal pain and sexual function in women. *J*
37
38 *Sex Med* 2010;7(2 Pt 1):645-653.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1– Some characteristics of women according to HIV status

Characteristic	Group		p Value
	HIV-infected (%) (n=128)	HIV-uninfected (%) (n=178)	
Age (years)			
40 – 44	43.8	24.7	<0.002 ¹
45 – 49	28.9	29.2	
50 – 54	15.6	23.1	
≥ 55	11.7	23,0	
Skin color			
White	35.2	47.2	0.047 ²
Non-White	64.8	52.8	
Number of deliveries			
Up to 1	25.0	25.4	>0.999 ²
≥2	75.0	74.6	
Marital status			
With partner	58.6	87.1	<0.001 ²
Without partner	41.4	12.9	
Schooling (years)			
≤7	62.5	40,4	<0.002 ¹
8-11	23.4	37,1	
≥12	14.1	22,5	
Employment status			
Yes	59.4	71.9	0.030 ²
No	40.6	28.1	
Menopausal status			
Premenopausal	39.8	24.7	<0.002 ¹
Perimenopausal	28.1	21.4	
Postmenopausal	32.1	53.9	
Current smoking t			
Yes/ Former	28,1	15.2	0.009 ²
No	71,9	84.8	
Physical activity			
Up to 2 times/week	77.3	74.2	0.614 ²
≥3 times/week	22.7	25.8	

¹Pearson's Chi-square; & Yates's Chi-square

Table 2 – Characteristics associated to HIV status associated with dyspareunia in women with sexual partner in the month before the interview (n=128)

Characteristics	N	%
HIV duration of infection (n=125) (years)	Mean: 9.5	SD: 5.06
Duration of HIV therapy (n=93) (years)	Mean: 8.7	SD: 4.47
Nadir CD4 levels (a)		
0 – 100	18	14.5
101 – 200	10	8.1
201 – 500	62	50.0
Last CD4 levels (a)		
0 – 100	5	4.0
101 – 200	1	0.8
201 – 500	43	34.7
> 500	75	60.5
Total	124	100.0
HIV risk factor for acquisition		
heterosexual acquisition	97	75.8
Illicit drug use	3	2.3
blood transfusion	2	1.6
	26	20.3

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Total	128	100.0
Use of TARV		
Yes	117	91.4
No	11	8.6
Total	128	100.0
(a) Missing information		

For peer review only

Table 3 – Factors associated with dyspareunia (score ≥ 2) in middle-aged HIV positive women: bivariate analysis

Variable	n	Dyspareunia%		p
		Score ≥ 2	Score <2	
Marital status				0.047
Married/live together	75	49.3	50.7	
Don't live together	53	30.2	69.8	
Did partner have HIV test?				0.020
Yes	88	50.0	50.0	
No	27	22.2	77.8	
Vaginal dryness				<0.001
Yes	53	58.5	41.5	
No	71	26.8	73.2	
Muscular / articular pain				0.021
Yes	83	49.4	50.6	
No	45	26.7	73.3	
Physical/ Emotional violence				0.049
Yes	128	55.5	44.5	
No	174	32.8	67.2	
Urinary Incontinence				0.004
Yes	41	61.0	39.0	
No	87	32.2	67.8	
Use of biovir				0.048
Yes	57	29.8	70.2	
No	63	49.2	50.8	

Table 4 – Variables associated with dyspareunia in HIV positive women with sexual partner in the month before the interview. Poisson multiple regression [n=124]

Variable	PR	95%CI	p-value
Vaginal dryness	1.96	1.10 – 3.50	0.023
Urinary incontinence	1.86	1.06 – 3.27	0.031

PR: prevalence ratio; CI 95%: 95% confidence interval; p: p-value

1
2
3
4
5
6 **Dyspareunia in HIV positive and negative middle-aged women: a cross –**
7 **sectional study**
8

9
10 Ana L. R. Valadares¹, MD, PhD; Aarão M. Pinto-Neto¹, MD, PhD; Debora de C.
11 Gomes¹, MD; Walquíria C. D'Avanzo³, Alexandre S. Moura, MD, PhD², Lúcia
12 Costa-Paiva¹, MD, PhD, Maria Helena de Sousa¹, PhD.
13
14

15
16
17
18 ¹ Department of Obstetrics and Gynecology, School of Medical Sciences,
19 University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.

20
21 ² Infectious Disease Reference Center, CTR/DIP Orestes Diniz, Municipal
22 Health Division, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.
23

24
25 ³ Graduated student of medicine of School of Medical Sciences, University of
26 Campinas (UNICAMP), Campinas, São Paulo, Brazil
27

28
29 **Corresponding author:**

30 Ana Lúcia Ribeiro Valadares

31
32 Rua Alexander Fleming, 101, Cidade Universitária Zeferino Vaz, Barão Geraldo
33
34 13083-881 Campinas, SP, Brazil
35

36 Telephone: 55 19 35219306

37 Fax: 55 31 35219354

38
39 E-mail: anarvaladares@gmail.com
40

41
42 **Running title:** Dyspareunia in HIV-positive women
43

44
45 **Short summary- word count:** 29
46

47 **Abstract- word count:** 250
48

49 **Text- word count:** ~~2646~~2786
50

Formatted: English (U.S.)

Key messages

- 41.4% of the HIV-positive middle aged women reported dyspareunia.
- Dyspareunia was mainly associated with vaginal dryness and urinary incontinence.
- HIV was not associated with dyspareunia. We hypothesize that it was because [HIV positive](#) women had [good immunovirological status](#) few HIV-related symptoms.

Formatted: Font: 12 pt

Short Summary

Cross-sectional study with 178 HIV-negative and 128 HIV-positive women of 40 to 60 years of age. Dyspareunia was common and was associated principally with vaginal dryness and urinary incontinence.

Abstract

Objectives: To evaluate whether dyspareunia is associated with HIV status in menopausal women and also to assess which factors are associated with dyspareunia in a group of HIV-positive menopausal women. **Methods:** A cross-sectional study was conducted with 178 HIV-negative and 128 HIV-positive women of 40 to 60 years of age. The Short Personal Experiences Questionnaire (SPEQ) was used to collect data. Sociodemographic, clinical, behavioral and reproductive factors were evaluated, as well as factors related to the HIV infection. Dyspareunia was defined as pain during intercourse. A bivariate analysis and Poisson multiple regression analysis were performed. **Results:** Overall, 41.4% of the HIV-positive women reported dyspareunia compared to 34.8% of the HIV-negative women ($p = 0.242$). In the HIV-positive

1
2
3
4
5
6 women, bivariate analysis revealed an association between dyspareunia and
7
8 having a steady partner ($p = 0.047$); the woman's partner having undergone HIV
9
10 testing ($p = 0.020$); vaginal dryness ($p < 0.001$); muscle/joint pain ($p = 0.021$);
11
12 physical/emotional violence ($p = 0.049$); urinary incontinence ($p = 0.004$); and the
13
14 use of lamivudine/zidovudine ($p = 0.048$). Poisson multiple regression analysis
15
16 found an association between dyspareunia and vaginal dryness (PR=1.96,
17
18 95%CI: 1.10-3.50, $p = 0.023$) and urinary incontinence (PR=1.86, 95%CI: 1.06-
19
20 3.27, $p = 0.031$). Conclusion: Dyspareunia was common in this group of HIV-
21
22 positive women and was associated principally with vaginal dryness and urinary
23
24 incontinence. The importance of treating dyspareunia within the context of
25
26 sexual health in this group of women should be emphasized and appropriate
27
28 management of this issue may reduce the likelihood of lesions on the vaginal
29
30 wall, which may act as a portal of entry for other infections.

31 **Keywords:** HIV; AIDS; dyspareunia; menopause; urogenital atrophy.
32
33

34 35 36 **Strengths and limitations of this study**

37 Strengths:

- 38
39
40
 - We have not found studies on dyspareunia in HIV positive women.
 - ~~There are few studies on dyspareunia in HIV positive women and almost none in middle-aged ones.~~

41
42
43
44
45
46
 - We have highlighted the importance of vulvovaginal atrophy and its association with dyspareunia in middle-aged HIV positive women.
 - We have showed that HIV infection was not significantly associated with dyspareunia, probably because HIV positive women had few HIV related symptoms.

47
48
49
50
51
52
53
54
55
56
57
58
59
60

- The results of this study may help physicians to pay attention on vulvovaginal atrophy and its consequences in this group of HIV positive women.

Limitations:

- It's a cross-sectional design study
- There were some differences in the clinical characteristics of the HIV-positive and HIV-negative women.

Introduction

Dyspareunia is defined as persistent or recurrent genital pain that occurs just before, during or after intercourse. It is one of the most common problems reported by menopausal women. The variation in the frequency of dyspareunia probably reflects many issues including sociocultural aspects, the period of observation during which the condition was evaluated (ever, the past year) and the duration or design of the study under discussion (questionnaire wording, participants).¹

For women of all ages, the pain caused by dyspareunia often results in distress, impaired sexual functioning and poor sexual enjoyment, difficulty in relationships and a poorer quality of life. In postmenopausal women, dyspareunia may also intensify personal issues related to aging, body image and health.²

-As with most of the sexual difficulties faced by women at midlife and beyond, dyspareunia is typically considered a consequence of declining ovarian hormone levels and is usually attributed to vaginal atrophy;³ however, other

1
2
3
4
5
6 factors may also be involved.⁴ In fact, psychosexual and biological factors
7
8 (including muscular, endocrine, immune, neurological, vascular and iatrogenic
9
10 factors) that predispose to, precipitate and perpetuate the condition may interact
11
12 to different degrees in the individual woman, contributing to a continuum of
13
14 symptoms of increasing severity, with the potential to impair sexual

15
16 intercourse.⁵⁻⁵ Age,⁶ depression, ~~nervousness~~ ~~anxiety~~ and sexual dysfunction
17
18 in the partner^{4,5} are some other factors associated with dyspareunia. It seems
19
20 that cognitive-emotional variables (catastrophization, depression, anxiety) are
21
22 significant predictors of dyspareunia and relationship adjustment variables were
23
24 inversely associated with pain severity.⁷ Findings also suggest that dyspareunia
25
26 impacts not only the psychosexual adjustment of affected women but also that
27
28 of their partners.⁸

Formatted: Superscript

Formatted: Superscript

Formatted: Superscript

29
30 Menopausal women who are HIV-positive may present a unique set of issues
31
32 that could affect their sexuality. These issues may include the meaning of their
33
34 illness, their quality of life, HIV transmissibility, and the dilemma of whether or
35
36 not to disclose the condition to their partner. Florence et al. reported sexual
37
38 dysfunction to be common in HIV-positive women, principally as a result of their
39
40 HIV status and of psychological factors that included depression, irritability and
41
42 anxiety.⁷⁻⁹ On the other hand, women with better mental health after HIV
43
44 diagnosis, a more positive attitude towards living with HIV, a better quality of
45
46 life, fewer HIV-related symptoms and who had never used injectable drugs were
47
48 found to have better sexual functioning.⁸⁻¹⁰ A possible role of antiretroviral
49
50 drugs in causing sexual dysfunction has been a matter of debate. Whereas
51
52 some studies have suggested that antiretroviral therapy indeed plays a role in
53
54 sexual function, others have failed to find any such association.^{9,11}

1
2
3
4
5
6 The majority of studies on dyspareunia have failed to deal with factors
7 associated with the HIV infection, a topic yet to be fully investigated in HIV-
8 positive women during the aging process. Therefore, the objectives of the
9 present study were to evaluate whether dyspareunia is associated with HIV
10 status in middle-aged women and to assess the factors associated with
11 dyspareunia in HIV-positive middle-aged women.
12
13
14
15
16
17
18
19

20 **Methods**

21 **Study design**

22
23
24 A cross-sectional study was conducted in which 537 women of 40 to 60 years of
25 age, 273 of whom were HIV-positive and 264 HIV-negative, were screened for
26 inclusion. Patients were recruited ~~These women were receiving care~~ at the
27 infectious diseases and HIV outpatient clinics (HIV positive women) and at the
28 menopausal ambulatory care (HIV negative women), both at the Teaching
29 Hospital of the University of Campinas (UNICAMP), ~~at the genital infections~~
30 ~~and the menopausal outpatient clinics of CAISM/UNICAMP, and~~ Patients were
31 also invited to participate at the infectious diseases outpatient public clinic (HIV
32 positive women)of the Eduardo de Menezes Hospital in Belo Horizonte ~~were~~
33 ~~invited to participate in the study.~~ Of these, 178 HIV- negative women and 128
34 HIV- positive women had had vaginal intercourse in the previous month and
35 were willing to answer a questionnaire on dyspareunia. These women were
36 then admitted to the study.
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51
52 For inclusion in the HIV-positive group, laboratory confirmation, through blood
53 samples collected at the moment of admission in the present study, of the
54
55
56
57
58
59
60

Formatted: Space After: 0 pt, Don't adjust space between Latin and Asian text, Don't adjust space between Asian text and numbers

1
2
3
4
5
6 women's seropositive status by one of the recommended tests (ELISA or
7 Western Blot) was required (all of them had it), while the women recruited to the
8 HIV-negative group had to have tested negative. The blood samples tests of
9 HIV negative and positive women were collected at the moment of admission in
10 the present study (FSH, LH and TSH for all, ELISA or Western Blot HIV tests for
11 HIV negative women and Viral load and CD4 cells for HIV positive women .
12 Exclusion criteria consisted of nursing mothers, bilaterally oophorectomized
13 women and those unable to answer the questionnaire.

14
15
16
17
18
19
20
21
22 The evaluation instrument was ~~based on~~ the Short Personal Experiences
23 Questionnaire (SPEQ).^{10,11,12,13} Sociodemographic, clinical, behavioral and
24 reproductive characteristics were assessed as well as issues relating to the HIV
25 infection and partner-related factors.

26
27
28
29
30 ~~Blood samples were collected at the moment of admission in the present study,~~
31 ~~and the rapid test was carried out and compared with the gold standard (ELISA~~
32 ~~and Western blot).~~

33 **Sample size**

34
35
36
37 ~~Sample size was calculated by estimating the prevalence of sexual dysfunction~~
38 ~~in HIV-negative menopausal women at 35.9%¹² and the prevalence of sexual~~
39 ~~dysfunction in HIV-positive women at 60.0%.¹³ To enable comparisons to be~~
40 ~~drawn between the HIV-positive and HIV-negative groups, the number of~~
41 ~~women required was calculated at 74 per group for an alpha error of 0.05 and a~~
42 ~~beta error of 0.20; however, to enable analysis to be made of the HIV-positive~~
43 ~~group alone, the required number was 188 women (with a difference of 7~~
44 ~~percentage points). Since the actual sample size achieved was 128, the~~
45 ~~absolute difference was 8.5%.~~

Dependent variable

The dependent variable dyspareunia, defined as pain during sexual intercourse, was graded from 1 to 6, where 1 referred to the absence of pain and 6 to maximum pain. A score of less than 2 was considered to represent the absence of dyspareunia and a score of 2 or more to represent the presence of dyspareunia. ^{12,13,14} ~~Dyspareunia was defined as pain during sexual intercourse in accordance with a pain intensity score of 2 or more within a scale of 1 to 6.~~

Independent variables

The independent variables were dichotomized as follows: HIV status (positive / negative); skin color (white / other); marital status (has a stable partner/ no stable partner); schooling (≤ 7 years / ≥ 8 years); employment (yes: / no); monthly family income (\leq USD750 / $>$ USD750); receives pension (yes / no); smokes (yes / never or past smoker); alcohol use (currently drinks or used to drink / never drank); hot flushes (yes / no); depression (yes / no); vaginal dryness (yes / no); urinary incontinence (yes / no); weight gain (yes / no); muscle and joint pain (yes / no); self-perception of health (excellent or good / poor or very poor); suffers or has already suffered some form of physical or emotional violence (yes / no); has been forced to have intercourse (yes / no); uses statins (yes / no); chronic disease: hypothyroidism (yes / no); FSH ($<40/\geq 40$), LH ($<25.7 / \geq 25.7$); age at first sexual intercourse (≤ 19 years / ≥ 20 years); other type of sexual intercourse in the preceding month: **active giving** oral sex (yes / no); ~~passive-receiving~~ oral sex (yes / no); woman lives with

Formatted: Line spacing: Double

1
2
3
4
5
6 sexual partner (yes / no); ~~menopausal status: (pre- or perimenopausal/~~
7 ~~menopausal)~~; number of sexual partners in the previous year (none / ≥ 1);
8
9 partner underwent HIV testing (yes / no); quality of life following diagnosis
10 (changed / unchanged); CD4 cell count (<350 / ≥ 350); CD4 cell count nadir
11 (<199 ; ≥ 200); use of antiretroviral drug 3TC (Lamivudine, Epivir) (yes/ no); use
12 of antiretroviral drug Tenofovir (yes / no); use of antiretroviral drug
13 lamivudine/zidovudine (yes / no); use of antiretroviral drug
14 Efavirenz (yes / no);
15 antiretroviral drug used in the past: lamivudine/zidovudine (yes / no);
16
17 antiretroviral drug used in the past: Efavirenz (yes/ no). Menopausal status was
18 classified as premenopausal, perimenopausal or postmenopausal. Women
19 were considered premenopausal if they continued to have regular menstrual
20 cycles similar to those present during the woman's reproductive life. They were
21 considered to be in the perimenopause if their menstrual cycles were irregular
22 and they had been amenorrheic for less than 12 months. Finally, women were
23 classified as postmenopausal if they had been amenorrheic for 12 months or
24 more.¹⁵ Data on physical activity was obtained through two questions: Do you
25 practice physical exercise or participate in sports every week? How often in a
26 week do you practice physical exercise or participate in sports?. It was
27 classified in up two times a week or 3 or more times a week. Vaginal lubrication
28 during sexual activity was graded from 1 to 6, where 1 referred to the absence
29 of lubrication and 6 to maximum lubrication. This was dichotomized into 4 or
30 less
31 or more than 4.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Statistical analysis

A bivariate analysis was performed in which dyspareunia was considered the dependent variable (dyspareunia) and analyzed as a function of the independent variables. Pearson's chi square test and the Yates correction were used to compare the groups.¹⁴⁻¹⁶ The Poisson multiple regression analysis¹⁵ ¹⁷ was adjusted in the various models for each one of the independent variables to evaluate the factors associated with the presence of dyspareunia.

Ethics

The study was approved by the internal review board of CAISM/UNICAMP and was conducted in compliance with the current version of the Declaration of Helsinki and with Resolution 196/96 of the Brazilian National Committee for Ethics in Research (CONEP) and its subsequent revisions. This study forms part of a larger study evaluating menopausal symptoms, bone mass, sexual function and metabolic markers. Process: CEP: 407/2010, CAAE 0313.0.146.000-10.

Women who agreed to participate in the study after receiving instructions from the researchers and who signed a free informed consent form were included.

Results

1
2
3
4
5
6 The HIV-positive women were younger and less likely to have a steady partner,
7
8 to be employed or to have a formal education compared to the HIV-negative
9
10 women. More than half the HIV-positive women were pre- or perimenopausal.
11
12 The characteristics of the women interviewed are shown in Table 1.

13
14 Overall, 41.4% (n=53) of the HIV-positive women and 34.8% (n=62) of the
15
16 HIV-negative women reported dyspareunia. There was no association
17
18 between HIV status and dyspareunia (p=0.242) ~~(data not shown as table).~~

19
20 Furthermore, in the multiple regression analysis of the entire sample of HIV-
21
22 positive and HIV-negative women taken together (n=306), dyspareunia was
23
24 not associated with HIV status, but was associated with vaginal dryness
25
26 (PR=2.06, 95%CI: 1.37-3.10, p=0.001) and urinary incontinence (PR=1.68,

27
28 95%CI: 1.14-2.46, p=0.008). ~~Predictive variables considered: HIV status
29
30 (positive / negative); skin color (white / other); marital status (has a stable
31
32 partner/ no stable partner); schooling (≤ 7 years / ≥ 8 years); employment
33
34 (yes: / no); monthly family income (\leq R\$1.500 / $>$ R\$1500); receives pension
35
36 (yes / no); smokes (yes / never or past smoker); alcohol use (currently
37
38 drinks or used to drink / never drank); hot flushes (yes / no); depression (yes
39
40 / no); vaginal dryness (yes / no); urinary incontinence (yes / no); weight gain
41
42 (yes / no); muscle and joint pain (yes / no); self-perception of health
43
44 (excellent or good / poor or very poor); suffers or has already suffered some
45
46 form of physical or emotional violence (yes / no); has been forced to have
47
48 intercourse (yes / no); uses statins (yes / no); chronic disease:
49
50 hypothyroidism (yes / no); LH (<25.7 / ≥ 25.7); age at first sexual intercourse
51
52 (≤ 19 years / ≥ 20 years); other type of sexual intercourse in the preceding
53
54 month: active oral sex (yes / no); passive oral sex (yes / no); woman lives~~

1
2
3
4
5
6 with sexual partner (yes / no); menopausal status: (pre- or perimenopausal/
7 menopausal); number of sexual partners in the previous year (none / ≥ 1).

8
9
10
11 ~~(Table not presented).~~

12
13
14 In the HIV-positive group, 91.4% of the women were currently in use of
15 antiretroviral therapy (ART) and, of these, 87% reported using ART regularly
16 (data not presented as table). Approximately 77% of the HIV-positive women
17 had a CD4 cell count nadir >200 . The most common way in which HIV had
18 been acquired was by heterosexual transmission, and the average duration of
19 the HIV infection was 9.5 ± 5.6 years (mean \pm SD), with a mean duration of
20 therapy of 8.7 ± 4.5 (mean \pm SD). A more detailed description of the HIV-
21 infected women is provided in Table 2.

22
23
24 Bivariate analysis revealed an association between dyspareunia in the HIV-
25 positive women and having a steady partner ($p=0.047$); the woman's partner
26 having undergone HIV testing ($p=0.020$); vaginal dryness ($p<0.001$);
27 muscle/joint pain ($p=0.021$); physical/emotional violence ($p=0.049$); urinary
28 incontinence ($p=0.004$); and the use of lamivudine/zidovudine ($p=0.048$),

29
30
31
32
33
34
35
36
37
38
39 Table 3.

40
41 According to the Poisson multiple regression analysis, the principal factors
42 associated with dyspareunia in the group of HIV-positive women were: vaginal
43 dryness (PR = 1.96; 95%CI: 1.10- 3.50; $p=0.023$) and urinary incontinence
44 (PR=1.86; 95%CI: 1.06-3.27; $p = 0.031$) (Table 4).

45 46 47 48 49 50 51 Discussion

Formatted: Justified, Right: 0.28", Space After: 10 pt, Tab stops: 5.25", Left + Not at 2.95"

1
2
3
4
5
6 The objectives of this study were to evaluate whether HIV status was
7
8 associated with dyspareunia and to assess the factors associated with pain
9
10 during sexual intercourse in HIV-positive women of 40 to 60 years of age.

11 The calculated number of women required for the sample size was at 74 per
12 group¹⁴; however, to enable analysis of the HIV-positive group alone, the
13 required number was 188 women¹⁸. Since the actual sample size achieved was
14 128, the absolute difference was 8.5%, acceptable since it is less than 10%.

15
16 Information on dyspareunia in HIV positive women is scarce, especially in
17
18 middle-aged women. To the best of our knowledge, no other studies have been
19
20 conducted on dyspareunia in HIV-positive women ~~of 40 to 60 years of age~~. It
21
22 has been reported that sexual function in HIV-positive women may be driven
23
24 principally by psychological factors and ~~by other problems originated by related to~~
25
26 HIV ~~status infection~~. ^{13,16,18,19} The present study, however, found that in the
27
28 overall sample of HIV-positive and negative women dyspareunia was not
29
30 affected by HIV status. This finding is in agreement with the results of another
31
32 author, who also reported that few women believed HIV in itself to be the cause
33
34 of any decline in their sexual functioning, since those women had good
35
36 immunovirological status - few HIV-related symptoms.^{8,10} One supposes that
37
38 results would be different in a sample of women without a good many HIV
39
40 symptoms control. In the present study, more than three-quarters of the HIV-
41
42 positive patients had a CD4 cell count nadir > 200 and CD4 cell counts > 500 in
43
44 their last evaluation, thus reflecting adequate control of the disease. This may
45
46 partially explain why no association was found between HIV status and
47
48 dyspareunia. In line with this, another study showed that women with CD4
49
50 counts ≤199 cells/μL reported poorer sexual functioning compared to those
51
52
53
54
55
56
57
58
59
60

Formatted: Font: 12 pt

1
2
3
4
5
6 whose cell count was ≥ 200 .⁴⁷²⁰ Other studies have shown that CD4 cell count
7
8 nadir may also have long-term consequences in terms of prognosis and
9
10 mortality.⁴⁸²¹

11
12 Nevertheless, the CD4 cell count nadir and the last CD4 evaluation were not
13
14 associated with dyspareunia in the present study, probably because of the small
15
16 number of women with these low values.

17
18 The most important factors associated with dyspareunia in the logistic
19
20 regression analysis, in HIV positive and negative groups analyzed together and
21
22 in the HIV group analysis were vaginal dryness and urinary incontinence, both
23
24 of which are urogenital disorders associated with estrogen deficiency. The
25
26 association between vaginal dryness and pain during sexual intercourse has
27
28 been well documented in the literature, in addition to its consequence on
29
30 vulvovaginal health.^{19,2022,23,24} With respect to the association between urinary

31
32 incontinence and dyspareunia, the findings of the present study are in
33
34 agreement with the results published by Salonia et al., ~~evaluated 216 women~~
35
36 ~~with urinary incontinence and found 44% of dyspareunia in these women. who~~
37
38 ~~compared 216 women with urinary incontinence to healthy women without any~~
39
40 ~~urinary symptoms and found 44% of dyspareunia in women with urinary~~
41
42 ~~incontinence.~~²¹²⁵ The type of urinary incontinence was not evaluated in the

43
44 present study. Nevertheless, there is good evidence that the effects of urinary
45
46 incontinence on sexual functioning are similar irrespective of whether the
47
48 condition has been classified as stress, urge, mixed incontinence²²²⁶ or even
49
50 interstitial cystitis²⁷ ~~Urinary incontinence leads to~~ is associated with feelings of
51
52 embarrassment and inadequacy as well as low self-esteem. It may also be
53
54 associated to dyspareunia.²²²⁵

Factors associated with dyspareunia in HIV positive women:

In the present study, more than three-quarters of the HIV-positive patients had a CD4 cell count nadir > 200 and CD4 cell counts > 500 in their last evaluation, reflecting adequate control of the disease. This may partially explain why no association was found between HIV status and dyspareunia. In line with this, another study showed that women with CD4 counts ≤ 199 cells/ μL reported poorer sexual functioning compared to those whose cell count was ≥ 200 .¹⁷ Other studies have shown that CD4 cell count nadir may also have long-term consequences in terms of prognosis and mortality.¹⁸ Nevertheless, the CD4 cell count nadir and the last CD4 evaluation were not associated with dyspareunia in the present study, probably because of the small number of women with these low values.

The most important factors associated with dyspareunia in the logistic regression analysis, in HIV positive and negative groups, were vaginal dryness and urinary incontinence, both of which are urogenital disorders associated with estrogen deficiency. The association between vaginal dryness and pain during sexual intercourse has been well documented in the literature.^{19,20} With respect to the association between urinary incontinence and dyspareunia, the findings of the present study are in agreement with the results published by Salonia et al., who compared 216 women with urinary incontinence to healthy women without any urinary symptoms and found 44% of dyspareunia in women with urinary incontinence.²¹ The type of urinary incontinence was not evaluated in the present study. Nevertheless, there is good evidence that the effects of urinary incontinence on sexual functioning are similar irrespective of

~~whether the condition has been classified as stress, urge or mixed incontinence. Urinary incontinence leads to feelings of embarrassment and inadequacy as well as low self-esteem. It may also lead to dyspareunia.~~²²

In the bivariate analysis, the fact that the woman's partner had not been tested for HIV was associated with less dyspareunia. It is reasonable to speculate that not knowing her partner's HIV status may in some way "minimize" a woman's concerns regarding transmission and reduce the probability of tension and dyspareunia.²³⁻²⁸ Another factor related to the sexual partner that was associated with an increase in dyspareunia in the bivariate analysis was the woman having a steady partner, although this association was borderline. One explanation for this finding may lie in the psychological problems generated by the infection itself, which may arise more frequently in stable relationships.

~~23,24,28,29 As one has not controlled for frequency of intercourse, one thought is dyspareunia due a lower frequency of intercourse rather than quality of the relationship.~~

Results of the bivariate analysis revealed an association between physical/emotional violence and dyspareunia. Violence is known to be associated with poorer psychological adjustment and adverse sexual health outcomes in women.^{25,26,30,31} In addition, having muscle pain was associated with dyspareunia in the bivariate analysis. This finding is in line with another study showing that musculoskeletal pain often interferes with sex and may be associated with dyspareunia.²⁷⁻³² A borderline association was found between the use of lamivudine/zidovudine and dyspareunia; however, no explanation for this association was found in the literature. One may hypothesize that

1
2
3
4
5
6 [dyspareunia in these women could be due depression side effects of these](#)
7 [drugs.](#)
8
9

10
11
12 Some limitations to the present study must be taken into account. First, its
13 cross-sectional design does not permit any conclusions to be drawn with
14 respect to causality. [It is also important to note that it was a clinical sample. So,](#)
15 [the results found in the present study may not be extrapolated to the general](#)
16 [population.](#) Furthermore, there were some differences in the clinical
17 characteristics of the HIV-positive and HIV-negative women. These differences
18 could be attributed to the fact that the HIV-negative women were selected at
19 specialist outpatient clinics providing care to menopausal women. [By selecting](#)
20 [HIV positive women also in menopausal outpatient care, maybe groups would](#)
21 [be similar.](#) Nevertheless, multivariate analysis, conducted in a sufficiently large
22 sample of women after controlling for confounding factors, confirmed that HIV
23 infection was not significantly associated with dyspareunia. Good control of the
24 HIV infection and the regular use of antiretroviral therapy by the majority of the
25 women may have brought this group of women closer to the HIV-negative group
26 in terms of their characteristics.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 **Conclusions**

46
47 In this study population, HIV infection was not associated with the presence of
48 dyspareunia. The principal factors associated with dyspareunia in HIV-positive
49 women were vaginal dryness and urinary incontinence. These data indicate a
50 need for multidisciplinary care for HIV-positive menopausal women, paying
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 particular attention to ensuring the women's compliance with antiretroviral
7
8 therapy and offering improved care when these two clinical situations are
9
10 present to ensure that these women come as close as possible in this respect
11
12 to HIV-negative women. Greater attention to dyspareunia as a potential
13
14 component of women's general HIV and sexual care is warranted. A proactive
15
16 approach to conversations about vulvovaginal atrophy would improve
17
18 management of dyspareunia and vaginal dryness. In addition to improving the
19
20 quality of these women's sexual life, we hypothesize that appropriate
21
22 management of this issue may reduce the likelihood of lesions on the vaginal
23
24 wall, which may act as a portal of entry for other infections.
25
26
27

28 **Financial Support:** The São Paulo Foundation for the Support of Research
29
30 (*Fundação de Amparo à Pesquisa do Estado de São Paulo - FAPESP*), Grant #
31
32 2010/06037-5.
33

34 **Competing Interest:** None declared.
35

36 **Licence statement**

37 The Corresponding Author has the right to grant on behalf of all authors and
38
39 does grant on behalf of all authors, an exclusive licence on a worldwide basis
40
41 to the BMJ Group and co-owners or contracting owning societies (where
42
43 published by the BMJ Group on their behalf), and its Licensees to permit this
44
45 article (if accepted) to be published in Sexually Transmitted Infections and any
46
47 other BMJ Group products and to exploit all subsidiary rights, as set out in our
48
49 licence.
50

51 Ana L R Valadares
52
53
54
55
56
57
58
59
60

List of contributors and their role in the paper

Conception or design of the work

Ana L. R. Valadares; Aarão M. Pinto-Neto; Lúcia Costa-Paiva

Acquisition of data for the work

Ana L. R. Valadares; Debora de C. Gomes, MD; Walquíria C. D'Avanzo, Alexandre S. Moura

Analysis of data for the work

Maria Helena de Sousa, Ana L. R. Valadares; Aarão M. Pinto-Neto; Lúcia Costa-Paiva

Interpretation of data for the work

Ana L. R. Valadares; Aarão M. Pinto-Neto; Lúcia Costa-Paiva, Maria Helena de Sousa

Drafting the work or revising it critically for intellectual content

Ana L. R. Valadares; Aarão M. Pinto-Neto; Lúcia Costa-Paiva; Debora de C. Gomes, MD; Walquíria C. D'Avanzo, Alexandre S. Moura, Maria Helena de Sousa

Final approval of the version to be published

Ana L. R. Valadares; Aarão M. Pinto-Neto; Lúcia Costa-Paiva; Debora de C. Gomes, MD; Walquíria C. D'Avanzo, Alexandre S. Moura, Maria Helena de Sousa

Competing interests: None declared

As corresponding author, I confirm that I have collected ICMJE Uniform

Disclosure Forms for Potential Conflicts of Interest from every author and no

Conflicts of Interest exist for any of the authors.

Data sharing

We confirm that is no additional unpublished data from the present study


available.

Extra data

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The instrument used to collect data is available by emailing
anarvaladares@gmail.com

For peer review only



References

- 1 Kao A, Binik YM, Kapuscinski A, Khalife S. Dyspareunia in postmenopausal women: a critical review. *Pain Res Manag* 2008;13:243-254.
- 2 Sung SC, Jeng CJ, Lin YC. Sexual health care for women with dyspareunia. *Taiwan J Obstet Gynecol* 2011;50:268-274.
- 3 Lachowsky M, Nappi RE. The effects of oestrogen on urogenital health. *Maturitas* 2009;63:149-151.
- 4 Valadares AL, Pinto-Neto AM, Conde DM, Sousa MH, Osis MJ, Costa-Paiva L. A population-based study of dyspareunia in a cohort of middle-aged Brazilian women. *Menopause* 2008;15:1184-1190.
- 5 Graziottin A. Etiology and diagnosis of coital pain. *J Endocrinol Invest* 2003;26(3 Suppl):115-121.
- 6 Avis NE, Zhao X, Johannes CB, Ory M, Brockwell S, Greendale GA. Correlates of sexual function among multi-ethnic middle-aged women: results from the Study of Women's Health Across the Nation (SWAN). *Menopause* 2005;12:385-398.
- 7 [Kao A, Binik YM, Amsel R, Funaro D, Leroux N, Khalifé S. Biopsychosocial predictors of postmenopausal dyspareunia: the role of steroid hormones, vulvovaginal atrophy, cognitive-emotional factors, and dyadic adjustment. *J Sex Med.* 2012 Aug;9\(8\):2066-76.](#)
- 8 [Pazmany E, Bergeron S, Verhaeghe J, Van Oudenhove L, Enzlin P. Sexual Communication, Dyadic Adjustment, and Psychosexual Well-Being in Premenopausal Women with Self-Reported Dyspareunia and](#)

Field Code Changed

1
2
3
4
5
6 [Their Partners: A Controlled Study. J Sex Med. 2014 Apr 1. doi:](#)
7 [10.1111/jsm.12518. \[Epub ahead of print\]](#)

8
9
10
11 ~~6~~

12
13 ~~79~~ Florence E, Schrooten W, Dreezen C, et al.; Eurosupport Study Group.
14 Prevalence and factors associated with sexual dysfunction among HIV-
15 positive women in Europe. AIDS Care 2004;16:550-557.

16
17
18
19 ~~810~~ Bova C, Durante A. Sexual functioning among HIV-infected
20 women. AIDS Patient Care STDS 2003;17:75-83.

21
22
23 ~~911~~ Collazos J. Sexual dysfunction in the highly active antiretroviral
24 therapy era. AIDS Rev 2007;9:237-245.

25
26
27 ~~1012~~ Dennerstein L, Anderson-Hunt M, Dudley E. Evaluation of a short
28 scale to assess female sexual functioning. J Sex Marital Ther
29 2002;28:389-397.

30
31
32
33 ~~1413~~ Valadares AL, Pinto-Neto AM, de Sousa MH, Osis MJ.
34 [Sociocultural adaptation of the short personal experiences questionnaire
35 (SPEQ) in Brazil]. Rev Bras Ginecol Obstet 2010;32:72-76.

36
37
38
39 ~~Valadares AL, Pinto-Neto AM, Osis MJ, Sousa MH, Costa-Paiva L, Conde DM.~~
40 ~~Prevalence of sexual dysfunction and its associated factors in women aged 40-~~
41 ~~65 years with 11 years or more of formal education: a population-based~~
42 ~~household survey. Clinics 2008;63:775-782.~~

43
44
45
46
47
48 [14 Valadares AL, Pinto-Neto AM, Conde DM, Sousa MH, Osis MJ, Costa-](#)
49 [Paiva L. A population-based study of dyspareunia in a cohort of middle-](#)
50 [aged Brazilian women. Menopause. 2008;15\(6\):1184-90](#)

51
52
53
54
55
56
57
58
59
60
Formatted: Portuguese (Brazil)

1
2
3
4
5
6 15 Soules MR, Sherman S, Parrott E, et al. Executive summary: Stages of
7 Reproductive Aging Workshop (STRAW) Park City, Utah, July, 2001.
8 Menopause 2001;8:402-407.
9

10
11
12 ~~12~~

Formatted: Portuguese (Brazil)

13
14 ~~13~~ 16 Lambert S, Keegan A, Petrak J. Sex and relationships for HIV
15 positive women since HAART: a quantitative study. Sex Transm Infect
16 2005;81:333-337.
17

18
19
20 ~~14~~ 17 Altman DG. Practical statistics for medical research. Boca Raton,
21 FL: Chapman & Hall/CRC, 1999.
22

23
24 ~~15~~ 18 Barros AJ, Hirkata VN. Alternatives for logistic regression in
25 cross-sectional studies: an empirical comparison of models that directly
26 estimate the prevalence ratio. BMC Med Res Methodol 2003;3:21.
27

28
29
30 ~~16~~ 19 Bell C, Richardson D, Wall M, Goldmeier D. HIV-associated
31 female sexual dysfunction: clinical experience and literature review. Int J
32 STD AIDS 2006;17:706-709.
33

34
35
36 ~~17~~ 20 Wilson TE, Jean-Louis G, Schwartz R, et al. HIV infection and
37 women's sexual functioning. J Acquir Immune Defic Syndr 2010;54:360-
38 367.
39

40
41
42 ~~18~~ 21 Bray S, Gedeon J, Hadi A, et al. Predictive value of CD4 cell count
43 nadir on long-term mortality in HIV-positive patients in Uganda. HIV AIDS
44 2012;4:135-140.
45

46
47
48 ~~19~~ 22 Laumann EO, Nicolosi A, Glasser DB, et al.; GSSAB Investigators'
49 Group. Sexual problems among women and men aged 40-80y:
50 prevalence and correlates identified in the Global Study of Sexual
51 Attitudes and Behaviors. Int J Impot Res 2005;17:39-57.
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 2023 Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is
7
8 strongly associated with female sexual dysfunction among sexually
9
10 active postmenopausal women. Menopause 2008;15(4 Pt 1):661-666.

11 24 Parish SJ, Nappi RE, Krychman ML, Kellogg-Spadt S, Simon JA, Goldstein JA,
12 Kingsberg SA. Impact of vulvovaginal health on postmenopausal women: a
13 review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health.
14 2013 Jul 29;5:437-47.

15
16 2425 Salonia A, Zanni G, Nappi RE, et al. Sexual dysfunction is
17
18 common in women with lower urinary tract symptoms and urinary
19
20 incontinence: results of a cross-sectional study. Eur Urol 2004;45:642-
21
22 648.

23
24 26 Urwitz-Lane R, Ozel B. Sexual function in women with urodynamic stress
25
26 incontinence, detrusor overactivity, and mixed urinary incontinence. Am J
27
28 Obstet Gynecol 2006;195(6):1758-61

29
30 27 Wehbe SA, Kellogg S, Whitmore K. Urogenital complaints and female
31
32 sexual dysfunction. Part 2. J Sex Med. 2010 Jul;7(7):2304-17

33
34
35
36
37 ~~22~~

38
39 2328 Reis RK, Gir E. [Living with the difference: the impact of
40
41 serodiscordance on the affective and sexual life of HIV/AIDS patients].
42
43 Rev Esc Enferm USP 2010;44:759-765.

44
45 2429 Klusmann D. Sexual motivation and the duration of partnership.
46
47 Arch Sex Behav 2002;31:275-287.

48
49 2530 Laanpere M, Ringmets I, Part K, Karro H. Intimate partner violence
50
51 and sexual health outcomes: a population-based study among 16-44-
52
53 year-old women in Estonia. Eur J Public Health 2013;23:688-693.

2631 Leclerc B, Bergeron S, Binik YM, Khalifé S. History of sexual and physical abuse in women with dyspareunia: association with pain, psychosocial adjustment, and sexual functioning. *J Sex Med* 2010;7(2 Pt 2):971-980.

2732 Rosenbaum TY. Musculoskeletal pain and sexual function in women. *J Sex Med* 2010;7(2 Pt 1):645-653.

Table 1– Some characteristics of women according to HIV status

<u>Characteristic</u>	<u>Group</u>		<u>p Value</u>
	<u>HIV-infected (%)</u> (n=128)	<u>HIV-uninfected (%)</u> (n=178)	
<u>Age (years)</u>			
<u>40 – 44</u>	<u>43.8</u>	<u>24.7</u>	<u><0.002¹</u>
<u>45 – 49</u>	<u>28.9</u>	<u>29.2</u>	
<u>50 – 54</u>	<u>15.6</u>	<u>23.1</u>	
<u>> 55</u>	<u>11.7</u>	<u>23.0</u>	
<u>Skin color</u>			
<u>White</u>	<u>35.2</u>	<u>47.2</u>	<u>0.047²</u>
<u>Non-White</u>	<u>64.8</u>	<u>52.8</u>	

<u>Number of deliveries</u>				
<u>Up to 1</u>	<u>25.0</u>	<u>25.4</u>	<u>>0.999²</u>	
<u>≥2</u>	<u>75.0</u>	<u>74.6</u>		
<u>Marital status</u>				
<u>With partner</u>	<u>58.6</u>	<u>87.1</u>	<u><0.001²</u>	
<u>Without partner</u>	<u>41.4</u>	<u>12.9</u>		
<u>Schooling (years)</u>				
<u><7</u>	<u>62.5</u>	<u>40.4</u>	<u><0.002¹</u>	
<u>8-11</u>	<u>23.4</u>	<u>37.1</u>		
<u>≥12</u>	<u>14.1</u>	<u>22.5</u>		
<u>Employment status</u>				
<u>Yes</u>	<u>59.4</u>	<u>71.9</u>	<u>0.030²</u>	
<u>No</u>	<u>40.6</u>	<u>28.1</u>		
<u>Menopausal status</u>				
<u>Premenopausal</u>	<u>39.8</u>	<u>24.7</u>	<u><0.002¹</u>	
<u>Perimenopausal</u>	<u>28.1</u>	<u>21.4</u>		
<u>Postmenopausal</u>	<u>32.1</u>	<u>53.9</u>		
<u>Current smoking t</u>				
<u>Yes/ Former</u>	<u>28.1</u>	<u>15.2</u>	<u>0.009²</u>	
<u>No</u>	<u>71.9</u>	<u>84.8</u>		
<u>Physical activity</u>				
<u>Up to 2 times/week</u>	<u>77.3</u>	<u>74.2</u>	<u>0.614²</u>	
<u>>3 times/week</u>	<u>22.7</u>	<u>25.8</u>		

¹Pearson's Chi-square; & Yates's Chi-square

Table 1—Characteristics of women according to HIV status

Characteristic	Group		p-Value
	HIV-infected (%) (n=128)	HIV-uninfected (%) (n=178)	
Age (years)			
—40—44	43.8	24.7	<0.002 #
—45—49	28.9	29.2	
—50—54	15.6	23.1	
—≥55	11.7	23.0	
Race/ethnicity			
—White	35.2	47.2	0.047 &
—Non-White	64.8	52.8	
Number of deliveries			
—Up to 1	25.0	25.4	>0.999 &
—≥2	75.0	74.6	
Marital status			
—With partner	58.6	87.1	<0.001 &
—Without partner	41.4	12.9	
Schooling (years)			
—≤7	62.5	40.4	<0.002 #
—8-11	23.4	37.1	
—≥12	14.1	22.5	
Employment status			
—Yes	59.4	71.9	0.030 &
—No	40.6	28.1	

Formatted: English (U.S.)

Menopausal status				
—Premenopausal	39.8	24.7	<0,002 #	
—Perimenopausal	28.1	21.4		
—Postmenopausal	32.1	53.9		
Smoking habit				
—Yes/ Former	28.1	15.2	0,009 &	
—No	71,9	84.8		
Physical activity				
—Up to 2 times/week	77.3	74.2	0,614 &	
—≥3 times/week	22.7	25.8		

* Sample of women with partner and information on occurrence or not of dyspareunia in the last month

Pearson's Chi-square; & Yates's Chi-square

Table 2 – Characteristics associated to HIV status associated with dyspareunia in women with sexual partner in the month before the interview (n=128)

<u>Characteristics</u>	<u>N</u>	<u>%</u>
<u>HIV duration of infection (n=125)</u> <u>(years)</u>	<u>Mean: 9.5</u>	<u>SD: 5.06</u>
<u>Duration of HIV therapy (n=93)</u> <u>(years)</u>	<u>Mean: 8.7</u>	<u>SD: 4.47</u>
<u>Nadir CD4 levels (a)</u> <u>0 – 100</u>	<u>18</u>	<u>14.5</u>

101 – 200	10	8.1
201 – 500	62	50.0
> 500	34	27.4
Last CD4 levels (a)		
0 – 100	5	4.0
101 – 200	1	0.8
201 – 500	43	34.7
> 500	75	60.5
Total	124	100.0
HIV risk factor for acquisition		
heterosexual acquisition	97	75.8
Illicit drug use	3	2.3
blood transfusion	2	1.6
	26	20.3
Total	128	100.0
Use of TARV		
Yes	117	91.4
No	11	8.6
Total	128	100.0

[\(a\) Missing information](#)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2 Characteristics associated to HIV status associated with dyspareunia in women with sexual partner in the month before the interview (n=128)

Characteristics	N	%
Nadir CD4 levels (a)		
0—100	18	14.5
101—200	10	8.1
201—500	62	50.0
>500	34	27.4
Last CD4 levels (a)		
0—100	5	4.0
101—200	4	0.8

201–500	43	34.7
> 500	75	60.5
Total	124	100.0
HIV risk factor for acquisition		
heterosexual acquisition	97	75.8
illicit drug use	3	2.3
blood transfusion	2	1.6
Não sabe/ Não respondeu	26	20.3
Total	128	100.0
Use of TARV		
Yes	117	91.4
No	11	8.6
Total	128	100.0
HIV duration of infection (n=125)	Mean: 9.5	SD: 5.06
(years)		
Duration of HIV therapy (n=93)	Mean: 8.7	SD: 4.47

(years)

(a) Missing information

Table 3 – Factors associated with dyspareunia (score >2) in middle-aged HIV positive women: bivariate analysis

Variable	n	Dyspareunia%		p
		Score>2	Score<2	
Marital status				0.047
Married/live together	75	49.3	50.7	
Don't live together	53	30.2	69.8	
Did partner have HIV test?				0.020
Yes	88	50.0	50.0	
No	27	22.2	77.8	
Vaginal dryness				<0.001
Yes	53	58.5	41.5	
No	71	26.8	73.2	
Muscular / articular pain				0.021
Yes	83	49.4	50.6	
No	45	26.7	73.3	
Physical/ Emotional violence				0.049
Yes	128	55.5	44.5	
No	174	32.8	67.2	

Urinary Incontinence

<u>Yes</u>	<u>41</u>	<u>61.0</u>	<u>39.0</u>	<u>0.004</u>
<u>No</u>	<u>87</u>	<u>32.2</u>	<u>67.8</u>	

Use of biovir

<u>Yes</u>	<u>57</u>	<u>29.8</u>	<u>70.2</u>	<u>0.048</u>
<u>No</u>	<u>63</u>	<u>49.2</u>	<u>50.8</u>	

Table 3—Factors associated with dyspareunia (score ≥ 2) in middle-aged HIV positive women: bivariate analysis

Variable	Dyspareunia%		p [*]
	N	Score ≥ 2	
Marital status			0.047
—Married/live together	75	49.3	50.7
—Don't live together	53	30.2	69.8
Did partner have HIV test?			0.020
Yes	88	50.0	50.0
No	27	22.2	77.8
Vaginal dryness			<0.001
—Yes	53	58.5	41.5

—No	71	26.8	73.2	
Muscular / articular pain				0.021
—Yes	83	49.4	50.6	
—No	45	26.7	73.3	
Physical/ Emotional violence				0,049
Yes	128	55.5	44.5	
-No	174	32.8	67.2	
Urinary Incontinence				0,004
Yes	41	61.0	39.0	
No	87	32.2	67.8	
Use of biovir				0.048
Yes	57	29.8	70.2	
No	63	49.2	50.8	

Predictive variables considered: skin color (white / other); marital status (has a stable partner/ no stable partner); schooling (≤ 7 years / ≥ 8 years); employment (yes: / no); monthly family income (\leq R\$1.500 / $>$ R\$1500); receives pension (yes / no); smokes (yes /

1
2
3
4
5
6 never or past smoker); alcohol use (currently drinks or used to drink / never drank); hot
7 flushes (yes / no); depression (yes / no); vaginal dryness (yes / no); urinary incontinence
8 (yes / no); weight gain (yes / no); muscle and joint pain (yes / no); self-perception of health
9 (excellent or good / poor or very poor); suffers or has already suffered some form of
10 physical or emotional violence (yes / no); has been forced to have intercourse (yes / no);
11 uses statins (yes / no); chronic disease: hypothyroidism (yes / no); LH (<25.7 / ≥ 25.7); age
12 at first sexual intercourse (≤ 19 years / ≥ 20 years); other type of sexual intercourse in the
13 preceding month: active oral sex (yes / no); passive oral sex (yes / no); woman lives with
14 sexual partner (yes / no); menopausal status: (pre- or perimenopausal/ menopausal);
15 number of sexual partners in the previous year (none / ≥ 1); partner underwent HIV testing
16 (yes / no); quality of life following diagnosis (changed / unchanged); CD4 cell count (<350 /
17 ≥ 350); CD4 cell count nadir (<199; ≥ 200); use of antiretroviral drug 3TC (Lamivudine,
18 Efavirenz) (yes/ no); use of antiretroviral drug Tenofovir (yes / no); use of antiretroviral drug
19 Lamivudine/zidovudine (yes / no); use of antiretroviral drug Efavirenz (yes / no);
20 antiretroviral drug used in the past: Lamivudine/zidovudine (yes / no); antiretroviral drug
21 used in the past: Efavirenz (yes/ no).
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 4 – Variables associated with dyspareunia in HIV positive women with sexual partner in the month before the interview. Poisson multiple regression [n=124]

<u>Variable</u>	<u>PR</u>	<u>95%CI</u>	<u>p-value</u>
<u>Vaginal dryness</u>	<u>1.96</u>	<u>1.10 – 3.50</u>	<u>0.023</u>
<u>Urinary incontinence</u>	<u>1.86</u>	<u>1.06 – 3.27</u>	<u>0.031</u>

PR: prevalence ratio; CI 95%: 95% confidence interval; p: p-value

~~**Tabela 4 – Variables associated with dyspareunia in HIV positive women with sexual partner in the month before the interview. Poisson multiple regression [n=124]**~~

<u>Variable</u>	<u>PR</u>	<u>95%CI</u>	<u>p-value</u>
.....			

Vaginal dryness	1.96	1.10—3.50	0.023
Urinary incontinence	1.86	1.06—3.27	0.034

PR: prevalence ratio; CI 95%: 95% confidence interval; p: p-value

Predictive variables considered: skin color (white / other); marital status (has a stable partner/ no stable partner); schooling (≤ 7 years / ≥ 8 years); employment (yes / no); monthly family income (\leq R\$1.500 / $>$ R\$1500); receives pension (yes / no); smokes (yes / never or past smoker); alcohol use (currently drinks or used to drink / never drank); hot flushes (yes / no); depression (yes / no); vaginal dryness (yes / no); urinary incontinence (yes / no); weight gain (yes / no); muscle and joint pain (yes / no); self-perception of health (excellent or good / poor or very poor); suffers or has already suffered some form of physical or emotional violence (yes / no); has been forced to have intercourse (yes / no); uses statins (yes / no); chronic disease: hypothyroidism (yes / no); LH (<25.7 / ≥ 25.7); age at first sexual intercourse (≤ 19 years / ≥ 20 years); other type of sexual intercourse in the preceding month: active oral sex (yes / no); passive oral sex (yes / no); woman lives with sexual partner (yes / no); menopausal status: (pre or perimenopausal/ menopausal); number of sexual partners in the previous year (none / ≥ 1); partner underwent HIV testing (yes / no); quality of life following diagnosis (changed / unchanged); CD4 cell count (<350 / ≥ 350); CD4 cell count nadir (<199 ; ≥ 200); use of antiretroviral drug 3TC (Lamivudine, Efavirenz) (yes / no); use of antiretroviral drug Tenofovir (yes / no); use of antiretroviral drug Lamivudine/zidovudine (yes / no); use of antiretroviral drug Efavirenz (yes / no); antiretroviral drug used in the past: Lamivudine/zidovudine (yes / no); antiretroviral drug used in the past: Efavirenz (yes / no).

checklist **Dyspareunia in HIV positive and negative middle-aged women**

	Item No	Recommendation
okTitle and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Ok background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Ok Objectives	3	State specific objectives, including any prespecified hypotheses
Methods		
Ok Study design	4	Present key elements of study design early in the paper
Ok Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Ok Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Ok Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Ok Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Ok Bias	9	Describe any efforts to address potential sources of bias
Ok Study size	10	Explain how the study size was arrived at
Ok Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Ok Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses

Continued on next page

Results

Ok Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Ok Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Ok Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Ok Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Ok Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

Discussion

Ok Key results	18	Summarise key results with reference to study objectives
Ok Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Ok Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Ok Generalisability	21	Discuss the generalisability (external validity) of the study results

Other information

Ok Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
------------	----	---

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.